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STUDY SUMMARY 
 
TITLE Development of a ready-to-use nutraceutical food for patients with sickle 
cell disease (SCD): Testing of vascular support components 
DESIGN Double-blinded, two-treatment, randomised, crossover clinical trial of a food 
based, 'nutraceutical' intervention. 
AIMS To develop a safe, deliverable, cost-effective intervention to improve the 
long-term health of sickle cell disease (SCD) patients in low-income 
countries. 
OUTCOME MEASURES The primary endpoints on which the trial is powered are growth velocities 
(height, weight and fat-free mass), plasma amino acid profiles and nitric oxide 
dependent endothelial function assessed by flow-mediated dilatation. 
POPULATION The study will enrol 120 children from within the Wellcome Trust supported 
hospital-based Muhimbili Sickle Cohort (MSC) (N≈2,000) at Muhimbili National 
Hospital, Dar-es-Salaam, Tanzania 
ELIGIBILITY Children will be eligible if they are enrolled in the MSC, resident in urban Dar-
es-Salaam and aged 8-11 years at enrolment.  
TREATMENT Treatments are assigned in random order consisting of: 
(A) 4-months of twice-daily lipid-based, ready-to-use supplementary food 
(RUSF), comprehensively fortified with vitamins and minerals (1 x RDA) 
and delivered with weekly chloroquine and daily placebo; or,  
(B) the same RUSF additionally fortified with arginine (L-Arg) and citrulline (L-
Cit) amino acids and delivered with daily chloroquine. 
DURATION Follow-up over 16 months. 
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PRIMARY ENDPOINTS
1. Plasma amino acids, arginase will be assessed at time points  0,1 & 3
2. Vascular function (flow mediated dilatation) will be assessed at time points 0, 1, 2 & 3
3. Growth (SCD-specific height-for age & BMI Z-scores) will be assessed at time points 0,1,2,3 & 4
 TIME 0 4 MONTHS TIME 1 4 MONTHS TIME 2 4 MONTHS TIME 3 4 MONTHS TIME 4 
INTERVENTION PERIOD 1 WASHOUT 1 INTERVENTION PERIOD 2 WASHOUT 2 
[N=60] RUSF + L-ARG/CIT + 
daily CQ
[N=60] RUSF + L-ARG/CIT + 
daily CQ
[N=60] RUSF + weekly CQ [N=60] RUSF + weekly CQ
16 MONTHS
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1. INTRODUCTION  
 
1.1 BACKGROUND 
Prevalence, morbidity, mortality and health burden of SCD in the African setting 
The homozygous inheritance of sickle haemoglobin (HbSS), is the most severe and predominant type of SCD. 
An estimated 7,800 children with HbSS are born annually in Tanzania, the 4th highest globally [1]. Current 
estimates suggest survival rates to adulthood of 20-50% in African settings [2], compared to up to 94% survival 
in the USA [3, 4] and up to 99% in the UK [5]. Improvements in public health in Africa are thought to be 
increasing the survival of infants [6] and the introduction of penicillin prophylaxis and pneumococcal 
vaccination, especially in the context of neonatal screening, will further decrease mortality in early life [2]. This 
gain will result in increased numbers requiring chronic care and place additional burden on limited health-care 
resources. It is estimated that 6 million people will be living with SCD in Africa [1]. In the near- to medium-term 
the costs and complexity of follow-up for interventions such as hydroxyurea (HU) therapy and prophylactic 
blood transfusions will make them difficult to implement outside of some tertiary level centres.  
Malnutrition in SCD 
Reduced growth has frequently been observed in SCD [7-9]. Energy and nutrient supplies are limited or 
perturbed in SCD from reduced dietary intake [10, 11], elevated metabolic rate [12-14], increased nutrient 
degradation and disturbed metabolic pathways [13, 15, 16].  
Vascular dysfunction in SCD 
In those that survive the first five years of life vasculopathy is an important cause of subsequent morbidity and 
mortality [17, 18]. A spectrum of endothelial dysfunction or “vasculopathy” has been documented that 
includes abnormal tone, responsiveness, structure and an activated and adhesive state of the vessels [19]. The 
many roles of the endothelium may be disrupted in SCD by several pathways (Figure 1). 
Figure 1. Probable hierarchies of implicated sub-biologies in SCD vasculopathy  
(taken from reference 19). 
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Polymerisation of sickle haemoglobin under hypoxic conditions causes sickling of red cells. This is thought to be 
the initiating cause of interacting downstream processes, causing vascular stasis and ischaemic reperfusion 
injury, leading to inflammation and activation of the endothelium. Intravascular haemolysis causes elevated 
oxidant stress, further endothelial and immune cell activation and decreased nitric oxide (NO) bioavailability. 
Plasma arginase is released from ruptured erythrocytes, platelets [20] and possibly from liver damage, resulting 
in abnormally high plasma levels [21]. Arginase degrades plasma arginine, the sole substrate of endothelial 
nitric oxide synthase (eNOS), thus limiting NO production. Ornithine is the degradation product from arginase 
activity and is a competitive inhibitor of arginine uptake by endothelial cells, thus the arginine:ornithine ratio 
may be critical to eNOS activity. Low plasma arginine is common in SCD [22], and is further decreased during 
vaso-occlusive episodes (VOC) and acute chest syndrome (ACS) [23]. Low plasma ratios of arginine to ornithine 
and high asymmetric di-methylated arginine (ADMA), an endogenous inhibitor of eNOS, are observed in SCD 
and are associated with increased pulmonary artery pressure and death in adult SCD patients [21, 24-26]. 
Reduced NO bioavailability is implicated as a key component in the pathophysiology of a range of severe 
morbidities in SCD and other disorders including malaria and cardiovascular disease [27-32].  
We propose that sub-optimal nutrition contributes to the processes involved in vascular pathology including 
haemolysis, NO bioavailability, vascular stasis, reperfusion injury, oxidative stress and hypoxia. This forms the 
basis for our proposed nutraceutical intervention for which the detailed supporting case and justification of 
dosages and choice of assessment methods is provided in Appendix 1. 
 
The Muhimbili Sickle Cohort (MSC) 
The Muhimbili Sickle Cohort was started in March 2004 with a Wellcome Trust clinical PhD fellowship awarded 
to Dr Julie Makani. As of May 2011 there were 1,613 enrolled SCD patients (HbSS) regularly attending clinic at 
Muhimbili National Hospital (MNH) (Figure 2) and resident in urban Dar-es-Salaam, with 118 documented 
deaths and 234 patients lost to follow-up. Newborn screening is not yet available; hence this represents a 
survivor cohort. Patients in the target 8-11y age group are prescribed daily folate. Clinical and laboratory data 
are collected, and samples stored from all routine clinic visits and during hospitalization.  We believe this may 
be the world’s largest single site SCD cohort. In the absence of newborn screening, the mortality rate is highest 
in the youngest age group 7.4/100 PYO [95% CI 4.8-11] in the under 5-year age group and 1.4/100 PYO [95% CI 
1.1-1.9] in the 5-19 year olds, (overall rate is 2.0/100 PYO [95% CI 1.5-2.9]) [33]. 
Figure 2. Age structure of 1613 HbSS enrolled patients currently attending MNH clinics on 1st May 2011 
(highlighting shows target age group for this trial). 
 
< 5 y,  
198, 12% 
5 - 7 y,  
260, 16% 
8 - 11 y,  
352, 22% 
12  - 17 y,  
398, 25% 
>=18,  
405, 25% 
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The MSC differs significantly from cohorts based in the USA, UK or Jamaica due to the near 100% of patients 
with HbSS, compared to the HbSC observed in diaspora populations of a West African origin (with its milder 
clinical course and lower mortality rate). Additionally a very high proportion of Tanzanian SCD patients (>90%) 
(Makani et al. unpublished data) have the Central African Republic (Bantu) haplotype associated with more 
severe disease and end-organ damage [34] compared to the Senegal, Benin or Arab haplotypes. This more 
severe sub-type of SCD strengthens the need for intervention and offers an appropriate location for this trial. 
Malnutrition in MSC 
The growth charts in Appendix 2 illustrate the profound growth retardation of patients in the MSC. From 
around 2 years old, median heights and weights are close to the 5th centile of the UK 1990 standards, with the 
greatest difference in teenage years (partly an artefact of delayed puberty). Local non-sickle controls are also 
stunted and underweight but even using these controls SCD predicts stunting (OR=1.82 [95%CI 1.43/2.32] 
P<0.001) and wasting (1.66 [1.21/2.28] P=0.002 respectively)[35]. Unsurprisingly, wasting was a predictor of 
hospital admissions: increasing 13% for each Z-score decrease in BMI [35]. Within the MSC, preliminary data 
indicate a mean age at Tanner Stage 2, when children normally experience increased growth rates, of 13.8y in 
boys and 14.1y in girls, and a mean age at menarche of 16y (N=54) (Jacob & Cox preliminary data). These data 
have determined our choice of the 8-11y age group, to avoid complications of puberty especially in interpreting 
growth effects, whilst being old enough for SCD to have initiated effects on the vascular system.   
Micronutrient status in the MSC 
Steady state concentrations of vitamins B and C and markers of iron status were measured in SCD and non-SCD 
controls as part of our previous WT-funded project grant (WT 80025).  Except for folate (patients receive 1 or 
5mg/d) the cohort exhibits high levels of deficiency according to standard cut-offs (58% for vitamin C, 57% for 
vitamin B6 and 45% for B12). Markers of iron status suggest a lower prevalence of iron deficiency in the MSC 
compared to local controls: transferrin saturation <16% = 25% [N=835] vs 47%[N=79] in controls. Moreover, 
our data suggest that higher iron status (but not iron overload) assessed by transferrin saturation is associated 
with lower daytime and nocturnal haemoglobin oxygen saturations [36]. Transferrin saturation is not 
associated with haemoglobin concentrations in SCD cases, compared to a strong correlation in the non-SCA 
controls, whilst adequate iron status assessed by the F-index (ratio of soluble transferrin receptor to logged 
ferritin), is paradoxically associated with greatly increased odds of having averaged steady state haemoglobin 
concentrations in the lowest septile (RR=5.45 [2.71/10.96] P<0.001). Hence iron will not be included in the 
fortificants of the current intervention.   
Amino acid status in MSC 
In a small pilot nested-case-control study, we assessed plasma amino acids in stored steady-state plasma 
samples from 11 SCD patients who had died (age at death 20.9±7.4y) compared to 12 matched survivors. In 
confirmation of results from adult patients in the USA [21], we found significantly lower ratios of arginine to 
ornithine (0.51±0.14 vs 0.68±0.17, p=0.014) in the patients who died [37]. Furthermore, plasma arginine and 
arginine:ornithine ratios  were significantly lower in our SCD patients compared to non-sickle children from 
Dar-es-Salaam  37±13 vs 120±10µmol/L and 0.60±0.18 vs 1.35±0.49 (Mwaikambo & Granger personal 
communication). Indeed plasma arginine was comparable to those observed in children with cerebral malaria 
(40µmol/L) [38]. 
 
1.2 RATIONALE FOR CURRENT STUDY 
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1.2.1 Study rationale 
Sickle cell disease (SCD) is the world’s most common single gene disorder affecting 300,000 births annually. In 
high-income countries, interventions and comprehensive care packages have greatly reduced mortality in 
children and young adults, though survivors still suffer significant disability and long-term organ damage. In 
sub-Saharan Africa, home to >70% of SCD patients, limited data suggests mortality is decreasing but morbidity 
and disability rates remain many fold higher. In low-income settings, the relative cost and complexity of 
standard therapies (routine blood transfusion and HU, for the prevention of complications may limit their 
widespread implementation. Alternative and complementary, logistically simple, safe and cost effective 
Interventions are required. 
 
The intervention is designed to target: 
i. the moderate to severe growth retardation commonly observed in children with SCD especially in low 
income countries; 
ii. endothelial dysregulation secondary to low NO bioavailability, inflammation and oxidant stress, 
hypothesised to underlie much of the clinical pathology in SCD, including risk of stroke, priapism, acute 
chest syndrome, vaso-occlusive episodes and eventual chronic end-organ damage in later life.  
If successful then larger studies of efficacy and effectiveness would be needed to assess long-term endpoints of 
hospitalization, stroke, and mortality. Existing evidence suggests that the proposed intervention also has the 
potential to increase the efficacy of HU therapy. 
The successful development of an affordable ready-to-use ‘nutraceutical’ food with proven efficacy in growth 
promotion and vascular health could represent a major step forward for SCD patients in low-income countries. 
1.2.2 Research questions  
1) Can provision of a comprehensively-fortified ready-to-use supplementary food (RUSF) reverse the 
growth retardation frequent in Tanzanian children with SCD? 
2) Can further supplementation with the NO substrates arginine and citrulline plus the addition of daily 
chloroquine (an arginase inhibitor) ameliorate vascular pathology by improving NO-dependent 
endothelial function, assessed by flow mediated dilatation? 
 
1.2.3 Study hypotheses 
This study will test the following hypotheses: 
1. That the provision of energy, protein and micronutrients within a ready to use supplementary food will 
increase linear growth, weight gain and proportion of fat-free mass children with SCD.   
2. That the provision of supplementary L-arginine and L-citrulline within the matrix of a twice-daily RUSF 
plus daily chloroquine (CQ) for 4 months, compared to a standard RUSF and weekly anti-malarial 
prophylaxis CQ to children with SCA will: 
a. Increase plasma arginine concentrations and the ratio of plasma arginine: orninthine. 
b. Decrease or not alter plasma ADMA concentrations 
c. Improve NO-dependent vascular function as detected by an increase in maximum flow 
mediated dilatation (FMDmax) 
3. That the provision of daily CQ at a dosage of 2-3mg base/kg/day for 4 months to children with SCA will: 
a. Decrease the activity of plasma arginase through competitive inhibition 
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b. Decrease levels of plasma inflammatory markers 
 
 
2.  STUDY OBJECTIVES 
 
The aims of this trial are to determine the effects of an RUSF on growth in a non-screened population of African 
children with SCD and to determine whether an RUSF fortified with L-arginine and L-citrulline, delivered with 
daily CQ, compared to the standard RUSF can increase NO bioavailability and consequent improved vascular 
endothelial function.  
 
The primary and secondary objectives are to detect effects on the selected endpoints as detailed below 
(Section3.2 Study outcome measures).  
 
 
3.  STUDY DESIGN 
 
The study comprises a random-ordered, double-blinded crossover clinical trial of two interventions with  4-
month washout periods – see Fig 3 below. A crossover design has been selected on the grounds of increased 
power and because we deemed the use of a control group receiving no RUSF to be potentially ethically 
questionable. The proposed design allows growth trajectories on RUSF to be compared to the adjacent 4 
month periods without RUSF. 
 
Fig 3 Study Design.  
 
 
120 children with confirmed SCD and enrolled in the MSC will be enrolled 
3.1 SAMPLE SIZE JUSTIFICATION 
The sample size of 120 has more than 99% power to detect a small, but potentially clinically relevant effect size 
(∆) of 1.25 unit change in FMDmax between the treatment arms, thus even if we allow for 33% drop outs or 
incomplete data at any of the time points, we will still have more than 95% power. Similarly a sample size of 
120 has more than 99% power to detect a 20% difference in growth rates for height and weight.  
 
3.2 STUDY OUTCOME MEASURES 
Primary endpoints:  
PRIMARY ENDPOINTS
1. Plasma amino acids, arginase will be assessed at time points  0,1 & 3
2. Vascular function (flow mediated dilatation) will be assessed at time points 0, 1, 2 & 3
3. Growth (SCD-specific height-for age & BMI Z-scores) will be assessed at time points 0,1,2,3 & 4
 TIME 0 4 MONTHS TIME 1 4 MONTHS TIME 2 4 MONTHS TIME 3 4 MONTHS TIME 4 
INTERVENTION PERIOD 1 WASHOUT 1 INTERVENTION PERIOD 2 WASHOUT 2 
[N=60] RUSF + L-ARG/CIT + 
daily CQ
[N=60] RUSF + L-ARG/CIT + 
daily CQ
[N=60] RUSF + weekly CQ [N=60] RUSF + weekly CQ
16 MONTHS
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1. Plasma amino acids and arginase levels and activity (Time points 0,1,2&3): Plasma for complete 
amino acid profiles including ADMA (by ion-exchange elution Biochrom-30, Biochrom, UK) and arginase 
analyses [39] will be separated and frozen immediately.  
2.  Assessment of vascular function (Time points 0,1,2&3): In a temperature controlled room, we will 
assess NO-dependent endothelial function by measuring brachial arterial dilatation with ultrasound 
(Siemens Accuson P50) in response to hyperaemia (5 min at 200 mmHg) induced after release of 
transient blood pressure cuff occlusion (Hokanson SC5), a technique known as flow mediated dilatation 
(FMD). Automated B-mode image edge detection will be used to calculate the maximum FMD 
percentage (FMDmax) as a change from resting baseline (Brachial Tools, Medical Imaging Applications) 
using a stereotactic holder with micrometer movement for the 12Mz probe [40, 41]. Endothelial-
independent responses to 25µg sub-lingual glyceryl-trinitrate (GTN) will also be measured. All 
measurements will be performed by a single operator trained by the Halcox group (see appendices for 
justification of choice of FMD and detailed FMD protocol). 
3. Anthropometry (Time points 0,1,2,3 & 4): Height, weight, lean body mass (LBM) and fat mass (FM) 
(Tanita BC418 segmental bio-impedance analyser) will be measured independently by two rigorously 
trained and cross-validated SP with real-time data-entry checks for acceptable ranges between 
readings. Equipment will be checked weekly and calibrated as necessary.  
Secondary endpoints: 
1. Haemoglobin concentration (Time points 0, 1, 2, 3 & 4): Full blood counts (FBC) of EDTA whole blood 
will be conducted (Pentra 60, Horiba ABX). 
2. Markers of inflammation and vascular activation [42-44] (Time points 0, 1, 2 & 3): Concentrations of 
soluble adhesion molecules (VCAM-1, VEGF-1, TNF-α & e-selectin, tissue factor  and IL-6) will be 
measured in frozen (-80⁰C) plasma aliquots (ELISA kits).  C-reactive protein concentrations will be 
measured in frozen serum samples (Architect C8000, Abbott Diagnostics) and leukocyte counts from 
FBC. 
3. Markers of haemolysis (Time points 0, 1, 2 & 3): plasma-Hb will be measured in frozen serum aliquots 
(ELISA, Bethyl Labs) and unconjugated bilirubin and lactate dehydrogenase in fresh serum (Architect 
C8000, Abbott Diagnostics).  
4. Estimated Glomerular filtration rate (eGFR)(Time points 0, 1, 2, 3 & 4): Serum createnine will be 
measured in fresh serum samples at all time points and used to estimate GFR using the Schwartz 
equation for children, or a modified version in which measured muscle mass is used in place of the 
estimated value in the k constant.  
5. Frequency of VOC-painful episodes: study personnel will administer detailed questionnaires at bi-
weekly home visits and by telephone in the intervening weeks to assess the frequency of all sickle and 
non-sickle associated morbidity and health seeking behaviour, with a focus on painful episodes. 
Participatory research will be used to determine the likely application and optimal formatting of pain 
diaries to be completed by patients and families in addition to the standard questionnaire.  
 
3.2 RISKS AND BENEFITS 
 
3.2.1 Potential benefits 
Participation in the trial should lead to benefits for all children as a result of increased contacts with health 
professionals both at the study clinic visits and through the weekly home-based visits by study personnel and 
increased rates of early detection and management of SCD-related events.  It is likely that the process of 
monitoring painful episodes at home will lead to improved management within the home and increased care-
seeking behaviour.  
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Both RUSF interventions are expected to increase growth and improve malnutrition in study participants 
(primary endpoint) and improve micronutrient status. Both the RUSF and RUSFv contain additional folate thus 
replacing the need for folate supplementation. Both RUSF interventions may increase steady-state 
haemoglobin levels (a secondary endpoint), both of which are likely to be associated with increased well-being 
and quality of life. Lower steady state haemoglobin level is associated with an increased risk of hospitalisation 
and mortality in the MSC and wasting with an increased risk of hospitalization [35]. The RUSFv may improve 
vascular function, the downstream effects of which could result in a reduction in the number and or severity of 
vaso-occlusive painful episodes, assessed as a secondary endpoint.  
3.2.2 Potential risks 
There are minimal safety concerns associated with these interventions.  
The level of micronutrient fortification is conservative at 1xRDA. Additional iron is not being included in the 
fortificants. In the absence of tolerable upper intake levels for amino acids, an observed safe level for long term 
use of L-arginine has been estimated at 20g/day for healthy adults, although few side-effects have been 
reported at much higher doses [45]. Whilst this is not available for L-citrulline, we can find no reports of side 
effects or toxicity associated with its use. No side effects were reported in a pilot phase II trial of L-citrulline in 5 
SCD adolescent subjects (approx 0.1g/kg/day). Similarly, no toxicity or negative effects have been reported in 
randomised trials of L-citrulline infusions in children undergoing heart surgery [46, 47], or 4 weeks oral 
supplementation (6g/day) in healthy adults [48]. Mild diarrhoea and intestinal disturbance has been proposed 
as a possible side effect of supplementation with these amino acids, from increased local NO production. 
However, a recent review of available studies concluded that gastro-intestinal side effects were only associated 
with single large doses of 9g or more [49].  
Chloroquine.  As with all drugs there are risks of experiencing side effects, adverse reactions, drug interactions 
and risk of overdose. The daily dose of chloroquine we will be giving is approximately half that recommended 
in BNF treatment guidelines for use in children with rheumatoid arthritis, whilst the weekly dose is as per 
current Tanzanian National Malaria Control Programme and British National Formulary (BNF) guidelines for use 
as a prophylactic. Long term-use of CQ has been associated with rare incidence of associated retinopathy and 
yearly ophthalmologic examinations are recommended by some authorities. Considering the short duration of 
the daily chloroquine and lower dosage, such outcomes are considered extremely unlikely. The risk of 
accidental over-dose is limited with both of our tested interventions due to the limited supply of CQ provided 
at any one time (please see 6.1).  
 
4. PARTICIPANT ENTRY  
 
4.1 PRE-RANDOMISATION OR PRE-REGISTRATION EVALUATIONS  
Pre-enrolment trial procedures include the following: 
Patient eligibility will initially be screened based on data available from the MSC database and hospital records 
(place of residence, age, SCD disease status, normal previous steady state liver and renal function tests and 
known illnesses – eg HIV). Parents of eligible children will be contacted by telephone or at scheduled routine 
outpatient clinics and these details confirmed and the presence of any known exclusion criteria checked (e.g. 
use of hydroxyurea) and if appropriate, informed about the trial and asked if they would consider for their child 
to participate.  On receipt of this verbal consent, we will make a study appointment at which full informed 
written consent will be sought, and if obtained, baseline examinations conducted.  
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4.2 INCLUSION CRITERIA 
 
• Aged 8-11 years old at enrolment and resident within urban Dar-es-Salaam  
• Enrolled in MSC and attending routine MNH sickle clinics 
• HbSS phenotype confirmed by electrophoresis and HPLC 
 
5.3 EXCLUSION CRITERIA 
• >95th percentile for body mass index (BMI) for age using British 1990 growth standards 
• Receiving HU therapy or significant other long-term drug therapy 
• Diagnosis with clinically significant non-SCD related disease including: 
o stage III or above HIV – or receiving ART therapy regardless of AIDS stage 
o Tuberculosis infection 
• Blood transfusion within previous 30 days 
• Previously diagnosed clinical pulmonary hypertension or cardiac dysfunction or clinical signs of  
pulmonary hypertension (loud pulmonary second heart sound) or heart failure (displaced apex beat, 
high jugular venous pressure, enlarged liver, peripheral oedema) 
• Low visual acuity at baseline (<6/9 using a modified (for Tanzania) Snellen chart or previously 
diagnosed chronic eye disorder likely to suggest  retinopathy or macular degeneration  
• Significant hepatic/renal dysfunction assessed by clinical chemistry panel at baseline 
• Epilepsy, psoriasis or currently taking any drugs listed as interacting with chloroquine 
 
 
4.4 WITHDRAWAL CRITERIA 
 
This trial is overseen by a Data Safety Monitoring Board (DSMB) operating under a charter.  The DSMB will 
monitor adverse events (AE’s) and severe adverse events (SAE’s) and advise the trial sponsor on whether the 
trial should be stopped or modified at any time due to safety or for implementation reasons. No interim 
analyses of the primary endpoints are planned. Participants who suffer SAE will be thoroughly investigated and 
the Trial Steering Committee (TSC), sponsor and statistician will be consulted. In the event of an SAE resulting 
in a death, the statistician will undertake an interim analysis of the number of AE by treatment within 1 month. 
At present, in the absence of an SAE occurring, the proposed strategy is to analyse the number of AE’s by 
treatment at 4 monthly intervals.  
 
Patients may withdraw at any stage without giving a reason and their clinical care will not be affected. If study 
participants wish to withdraw their consent from the study at any time, they will be asked if they are willing to 
give permission for archived samples to be used for study analyses. Written consent will be required in order 
for this to occur. If consent is not provided, archived samples will be destroyed and data will not be used in 
analyses of study outcomes, but may be used in comparisons of baseline data between groups of patients, 
screened, randomised, completed and drop-outs.  
 
5. RANDOMISATION AND ENROLMENT PROCEDURE 
 
5.1 RANDOMISATION & BLINDING 
Study sample ID numbers will be generated in advance and block randomised (in blocks of 12) to one of the 
four treatment codes for each of the two treatment periods. Participants will be assigned the next sequential 
study ID at enrolment.  The allocation code (representing the 4 shapes used on the RUSF packets) indicating 
the contents (RUSFv vs. RUSF) will be generated by the RUSF manufacturer and known only to the producer, 
the DSMB and the study pharmacist. The same allocation code will be used by the study pharmacist when 
making up and dispensing participant CQ syrup bottles each week (see section 6.X).  Packages of RUSFv and 
RUSF will be delivered by the producer in lots designated by allocation code. The manufactuer of the CQ and 
placebo syrups will deliver these in 5L containers, manufactured as single lots to the study site. The trial 
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pharmacist will make up the CQ and placebo bottles for the trial participants using the study ID randomisation 
list, allocation code and weight category information collected at baseline. Participants will be recruited to 
sequential study IDs after having signed consent forms and completed baseline assessments. Participants will 
be asked on exit from the study if they could guess their treatments. 
 
5.2 UNBLINDING 
Reporting of SAEs and SUSARs will not require un-blinding of the research staff managing the day to day 
activities of the trial. Un-blinded data will only be available to the DSMB.  
 
6. TREATMENTS 
 
6.1 TREATMENT ARMS 
Both interventions will consist of twice-daily RUSF in single portion packs, comprehensively fortified with 
vitamins and minerals at approximately 1xRDA (except for folate [1mg/day] and iron [not included in the 
fortificants]) providing 500kcal/d (Table 1). The simple RUSF will be given with placebo base syrup on 6/7 days 
and chloroquine (malaviron, Wallace Manufacturing Chemists, UK) every 7th day to match the anti-malarial 
action of chloroquine in the vascular arm and as per Tanzanian guidelines. The enhanced ‘vascular-RUSF’ 
(RUSFv) will be additionally fortified with L-arginine and L-citrulline depending on subject weight (<or≥ 25kg, 
median weight is 24kg in this age range) to achieve mean intakes of 0.2g L-Arg and 0.1g L-Cit/kg/day and 
maximum intakes of 0.33/0.165g/kg/d. The RUSFv will be given with daily chloroquine syrup to achieve a 
maximum dose of 3mg base/kg/day (Figure 4).  
Table 1. Detailed amino acid and micronutrient composition of RUSF intervention 
 
Daily 
dose RUSF (placebo) RUSFv (low, <25kg) RUSFv  (high, >25kg) 
Calories total  
Kcal 500 500 500 
Proteins  
g 
13 13 13 
Arginine  
g 0 5 7,5 
Citrulline  
g 
0 2,5 3,75 
Vitamin A / Retinol µg 600 600 600 
Vitamin B1 / Thiamine mg 1,1 1,1 1,1 
Vitamin B2 / Riboflavin mg 1 1 1 
Vitamin B3 / Niacin mg 16 16 16 
Vitamin B5 / Pant. Acid mg 5 5 5 
Vitamin B6 / Pyridoxine mg 1,2 1,2 1,2 
Vitamin B8 / Biotin µg 25 25 25 
Vitamin B9 / Folate µg 1000 1000 1000 
Vitamin B12 / Cobalamin µg 2,4 2,4 2,4 
Vitamin C / Ascorbate mg 45 45 45 
Vitamin D / Calciferol µg 15 15 15 
Vitamin E / Tocopherol mg 11 11 11 
Vitamin K  µg 55 55 55 
Phosphor mg 1250 1250 1250 
Calcium mg 1300 1300 1300 
Potassium mg 4,5 4,5 4,5 
Iodine µg 120 120 120 
Iron mg 0 0 0 
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Magnesium mg 240 240 240 
Selenium  µg 40 40 40 
Copper µg 700 700 700 
Zinc mg 11,2 11,2 11,2 
Sodium g low low low 
The RUSF will be manufactured to GMP standards, by Nutriset, France, with batch certificates and following 
recommended International Code of practice for foods for infants and children of the Codex Alimentarius 
Standard CC/RCP 21-1979 and ISO22000 standards.  
 
The chloroquine syrup and placebo base syrup will be purchased from Wallace Manufacturing Chemists, UK,  
manufactured to GMP standards.  
 
The RUSF product is being provided by Nutriset at a flat-rate research cost of 3 Euros/Kg. The product will be 
delivered to the research site in 2 shipments and will be stored in a dedicated room at room temperature, with 
stock monitoring and tracking protocols, with access to remove stock restricted to named staff.  
Figure 4. RUSF fortification formulation per sachet pack (to be consumed twice daily) 
 
Dosage of L-arginine and L-citrulline 
 The final targeted dosages of the amino acids (0.2g/kg/d for L-arginine plus 0.1g/kg/d for L-citrulline) 
were chosen on the basis of three criteria: 1) safety; 2) evidence of efficacy; and 3) limitations on the amounts 
that can be incorporated into the RUSF, whist maintaining sufficiently high energy-density, taste and textural 
properties.  
The observed safe level (OSL) for L-arginine is 20g/day in healthy adults (please see below). This is 
equivalent to 0.33g/kg/d assuming an average adult weight of 60kg. Doses of 0.1-0.2g/kg/day of L-arginine [50, 
51] & L- citrulline [52] have been utilized previously in SCD subjects with no adverse effects or toxicities 
reported and resulted in significant increases in plasma arginine concentrations. Three months’ L-arginine 
  
  < 25 Kg   
[expected range 15 - 24.9  kg]  
>   =25 kg    
[expected range 25 - 40  kg]  
  RUSF  RUSFv  RUSF  RUSFv  
Chloroquine  150 mg  weekly *  50  mg   daily †  225  mg  weekly *  75  mg  daily †  
L - A rginine  --  2.5 g  --  3.75 g  
L - Citrulline  --  1.25 g  --  1.875g  
F olate   0.5 mg   0.5  mg   0.5 mg   0.5 mg   
Energy kcal  250  250  250  250  
All formulations will be fortified  to achieve   daily intakes of    approx 1x  Reference Nutrient Intake (WHO /   UK ) or  
Recomm ended   Daily Allowance (USDA) , whichever is the higher   of the following vitamins and minerals :   
V itamins  A, B1, B2, B6, B12, C, D, E, K, biotin, pantothenic acid, niacin,  potassium, calcium, phosphorus  
( excluding phytate) , magnesium,  zinc, coppe r, selenium, iodine and  manganese .    
No ad ditional iron will be included in the fortificant mix.   
*BNF for children 2007 p390,  chloroquine    for malarial prophylaxis    
† BNF for children 2007 p573 ,  chloroquine use in  juvenile active  rheumatoid   arthritis/ systemic & discoid lupus  
erythromatosus   
All added mineral salts and vitamins are on the advisory list of mineral salts  and   vitamin compounds for use in  
foods for infants  and  children of  the   Codex Alimentarius Standard CAC/GL10 - 1979.    
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supplementation (0.1-0.2g/kg/d) increased plasma arginine over time from baseline (50.1+/-17.0 µMol/L, N=8) 
to a near 100% increase at 12 weeks [50].  
A lower dose of L-citrulline compared to L-arginine is proposed based on: i) doubled or greater AUC 
plasma arginine responses compared to L-arginine [53]; ii) relative expense of L-citrulline compared to L-
arginine; and iii) less evidence available to determine observed safe levels.  
 
Packaging of the interventions 
The daily RUSF rations will come in 2 chains of 7 packets. Each chain of 7 will be numbered 1-7 and labelled 
with the corresponding day of the week with arrows printed pointing from 1 to 7 (Figure 5a & b). The 
chloroquine and placebo base syrup will be provided as amber coloured translucent plastic bottles of 2 
different sizes (400ml & 100ml) with safety dispenser caps and appropriate labelling to each participant. In the 
weekly CQ intervention, the larger bottle will contain placebo base syrup enough to provide 2 weeks, plus 2 
extra days (14 daily doses) of supply and the smaller bottle will contain 2 weeks supply of the the CQ syrup (2 
daily doses). Participants will receive instructions to take a daily dose from the small bottle containing teh 
active CQ syrup on the same day every week (Sundays) and doses from the large bottle the remaining days. In 
the daily CQ intervention, participants will receive the same two bottles with instructions to take doses from 
the small bottle on the sundays and doses from the other bottle the remaining days, but both bottles will 
contain chloroquine syrup, diluted to the appropriate daily dose using the placebo syrup.  
Figure 5a Individual packets showing randomisation code options 
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Fig 5b Proposed Final RUSF packaging in strips with Swahili labelling 
 
 
6.2 DOSE MODIFICATIONS FOR TOXICITY  
 
Not applicable 
 
6.3 PREMEDICATION 
 
No drugs are to be prescribed as part of the study protocol.   
 
6.4 INTERACTION WITH OTHER DRUGS 
 
Of the list of drugs with reported possible interactions with chlororquine (BNF 2011), none are expected to be 
used during the current study.  Please see Appendix 2 for a summary of these.  
 
 
6.5 DISPENSING AND ACCOUNTABILITY 
 
The RUSF, chloroquine and placebo syrups will be delivered by the manufacturer to the research site. 
Thereafter, the RUSF & chloroquine will be delivered to the dedicated trial storage area. Only designated 
persons will have access to the RUSF & chloroquine and protocols will be in place to monitor stocks and 
distribution of the supplements to patient’s families, to be done during home visits by a study field worker.  
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7. SAFETY REPORTING 
 
7.1 DEFINITIONS   
Adverse Event (AE): any untoward medical occurrence in a patient or clinical trial subject administered a 
medicinal product and which does not necessarily have a causal relationship with this treatment.  An AE can 
therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or 
disease temporally associated with the use of an investigational medicinal product (IMP), whether or not 
considered related to the IMP. 
 
Adverse Reaction (AR): all untoward and unintended responses to an IMP related to any dose administered.  
All AEs judged by either the reporting investigator or the sponsor as having reasonable causal relationship to a 
medicinal product qualify as adverse reactions.  The expression reasonable causal relationship means to convey 
in general that there is evidence or argument to suggest a causal relationship. 
 
Unexpected Adverse Reaction: an AR, the nature or severity of which is not consistent with the applicable 
product information (e.g. investigator’s brochure for an unapproved investigational product or summary of 
product characteristics (SmPC) for an authorised product).  When the outcome of the adverse reaction is not 
consistent with the applicable product information this adverse reaction should be considered as unexpected.  
Side effects documented in the SmPC which occur in a more severe form than anticipated are also considered to 
be unexpected. 
 
Serious Adverse Event (SAE) or Serious Adverse Reaction: any untoward medical occurrence or effect that at 
any dose 
• Results in death 
• Is life-threatening – refers to an event in which the subject was at risk of death at the time of the 
event; it does not refer to an event which hypothetically might have caused death if it were more 
severe 
• Requires hospitalisation, or prolongation of existing inpatients’ hospitalisation 
• Results in persistent or significant disability or incapacity 
• Is a congenital anomaly or birth defect 
 
Medical judgement should be exercised in deciding whether an AE/AR is serious in other situations.  Important 
AE/ARs that are not immediately life-threatening or do not result in death or hospitalisation but may jeopardise 
the subject or may require intervention to prevent one of the other outcomes listed in the definition above, 
should also be considered serious. 
 
Suspected Unexpected Serious Adverse Reaction (SUSAR): any suspected adverse reaction related to an IMP 
that is both unexpected and serious.   
 
7.2 CAUSALITY 
Most adverse events that will occur in this study are likely to be as a result of ongoing sickle cell disease, such 
as vaso-occlusive painful episodes (please see Appendix 4). For the purposes of this study, an expected SAE is 
an adverse event that is serious, expected and likely related to the subject’s underlying disease process. For 
this study, AEs listed in Table 2 are expected SAEs. Recording these will be particularly important in this trial as 
the intervention may change the pattern of complications. 
Adverse drug reactions, whether they are serious or not, will be expected treatment-related toxicities due to 
choroquine (please see Appendix 2).  The assignment of the causality will be made by the investigator 
responsible for the care of the participant using the definitions in the table below. 
 
If any doubt about the causality exists the trial coordinator will notify the Chief Investigator. Chloroquine 
manufacturing pharmaceutical companies and/or other clinicians may be asked to advise in some cases. 
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In the case of discrepant views on causality between the investigator and others, all parties will discuss the 
case.  In the event that no agreement is made, the Tanzanian Food & Drug Authority will be informed of both 
points of view.  
 
Relationship Description 
Unrelated There is no evidence of any causal relationship 
Unlikely There is little evidence to suggest there is a causal relationship (e.g. the event did not 
occur within a reasonable time after administration of the trial medication).  There is 
another reasonable explanation for the event (e.g. the participant’s clinical condition, 
other concomitant treatment). 
Possible There is some evidence to suggest a causal relationship (e.g. because the event occurs 
within a reasonable time after administration of the trial medication).  However, the 
influence of other factors may have contributed to the event (e.g. the participant’s 
clinical condition, other concomitant treatments). 
Probable There is evidence to suggest a causal relationship and the influence of other factors is 
unlikely. 
Definitely There is clear evidence to suggest a causal relationship and other possible 
contributing factors can be ruled out. 
Not assessable There is insufficient or incomplete evidence to make a clinical judgement of the causal 
relationship. 
 
7.3 REPORTING PROCEDURES 
All AE’s will be reported.  Depending on the nature of the event the reporting procedures below will be 
followed according to a modified version of London School of Hygiene & Tropical Medicine (LSHTM) standard 
Operating Procedures (SOP) for reporting of AE’s and SAE’s (SOP LSHTM/SOP/010a V2), taking into account 
local reporting requirements.  Any questions concerning adverse event reporting will be directed to the Trial 
Coordinator, Dr Beatrice Kamala in the first instance.  A flowchart is given in appendix 5 to aid in the reporting 
procedures. 
 
7.3.1 Non serious Adverse Reactions (ARs)/Adverse Events (AEs) 
All such events, whether expected or not, will be recorded in the appropriate AE CRF and entered into the 
research database within one week.   
 
7.3.2 Serious Adverse Reactions (SARs)/Serious Adverse Events (SAEs) 
All fatal serious SAEs, SARs and SUSARs will be reported on the day trial staff are aware of the event (within 
24h).  All SAEs, regardless of outcome will be reported to the local regulatory authority, the Tanzanian Food & 
Drug Authority, (TFDA) and the Tanzanian national ethics Committee (TNEC) within 14 days.   The SAE form asks 
for nature of event, date of onset, severity, outcome and causality (i.e. unrelated, unlikely, possible, probably, 
definitely).  The responsible investigator Dr Julie Makani or Prof C Newton or designated medically qualified 
study personnel will sign the causality of the event.  Additional information should be sent within 5 days if the 
reaction has not resolved at the time of reporting.   
 
SAEs 
An SAE form should be completed and sent to the CI & Prof F Kirkham (see contacts below) for all SAEs within 
24 hours.  However, hospitalisations for elective treatment of a pre-existing condition do not need reporting as 
SAEs. 
 
SUSARs  
In the case of serious, unexpected and related adverse events, trial staff will:  
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 Complete the SAE case report form & send it immediately (within 24 hours as scanned e-mail 
attachment), signed and dated to Dr Cox & Prof Kirkham together with relevant treatment forms and 
anonymised copies of all relevant investigations. 
 
The CI, S Cox and Prof F. Kirkham will be responsible for reporting all fatal or life threatening SUSARs occurring 
during the study to the Tanzanian Food & Drug Authority, Tanzanian National Ethics Committee within 24h of 
notification and within 7 days to LSHTM & MUHAS ethics committees. Non-fatal or life-threatening will be 
notified to the above authorities within 14 days.   All investigators will be informed of all SUSARs occurring 
throughout the study. SAE’s will be similarly reported.  
 
Contact details for reporting SAEs and SUSARs 
Please send SAE forms to: f.kirkham@ich.ucl.ac.uk & Sharon.cox@LSHTM.AC.UK  
Tel: +44 0208 743 2980/ +255 755 406115   
 
 
8. ASSESSMENT AND FOLLOW-UP  
 
Participants will be followed up for a total of 16 months from enrolment. All participants will be seen at 4 clinic 
research-specific visits, 4 months apart (please see Figure 3) at which a clinical history and examination 
including detailed anthropometry, temperature, respiratory rate and blood pressure will be conducted. A 5 ml 
blood sample will also be taken and assessment of flow mediated dilatation will take place (please see section 
3.2 for description of assessments and appendix 3 for a schedule of events table.  In addition, participants will 
be seen throughout the study period at bi-weekly home visits by a study field worker, who will deliver the 
intervention (during the intervention periods). At these visits parents/guardians will be asked to assist in the 
completion of a short questionnaire concerning adherence to the intervention, report any illnesses, sickle ad 
non-sickle related and health seeking behaviour and return the home diaries monitoring the incidence, 
duration and severity of painful episodes, to be completed by children with parental assistance. In the 
intervening weeks, an adapted version of the same questionnaire will be administered by telephone. In 
addition subsets of children will be seen clinic visits at 1, 2 and 3 months after enrolment (40 children per time 
point) during the first intervention period for interim assessments of FMD to provide data to determine of FMD 
responses are limited to short term effects and for additional safety monitoring through collection of a 2ml 
blood sample for full blood picture and clinical chemistry assessment of liver and kidney function.  
 
8.1 LOSS TO FOLLOW-UP 
If participants are not found during weekly home visits, families will be contacted by telephone immediately 
and a new appointment made. If participant families cannot be contacted by phone a further home visits at 
usual time the following week will be conducted. If participants fail to attend a clinic visit they will be 
telephoned the same or following day and another appointment scheduled. Participants who are unable to be 
traced or contacted for 4 weeks or more will be deemed loss to follow-up.  
 
8.2 DATA SECURITY & TRIAL CLOSURE  
8.2.1 Data security 
Brachial FMD scans will be backed up onto an external hard drive at the end of each day. A further copy of the 
scans will be uploaded onto the main server. The FMD scans will be analysed offline on the computer they 
were recorded on. These completed analyses will also be backed up daily onto an external hard drive and the 
main server) 
Off-site data back-up of the MSC server is conducted nightly with encrypted data sent to a server hosted by 
Uhurunet.com over a secure connection.  
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Paper records will be securely stored in the MSC office. Informed consent documents will be electronically 
scanned and stored on the MSC server linked to the study and MSC database. The three computers to hold 
study data (the desktop recording and used for offline analysis of the echo data, the laptop for the study 
coordinator and the PI laptop) will be encrypted and have software loaded allowing remote deletion of all 
stored data on the hard-drives, in the event that the computer is stolen. 
8.2.2 Trial close out 
 
At the end of the trial, whether stopped early or at the end of recruitment procedures will be followed to 
ensure the following are completed: 
• All investigational products (RUSF & chloroquine) are accounted for and returned (RUSF to Nutriset) or 
destroyed; 
• GCP documents are complete and archived; 
• Trial documents including participant log, randomisation codes, product batch numbers, CRFs, signed 
consent documents are archived; 
• A trial report is produced, capturing all the key data and stating where key documents are archived;  
• Trial results and the trial report are disseminated to all the appropriate parties, including but not 
limited to: the regulatory authority (TFDA), the ethical committees (Tanzanian NEC, MUHAS & LSHTM), 
Tanzanian MoH and Muhimbili National Hospital, Tanzanian Sickle Cell Foundation, the study 
participants and the trial sponsor (LSHTM).  
Data and all appropriate documentation will be securely stored for a minimum of 5 years after the completion 
of the study, including the follow-up period.   
 
9. STATISTICS AND DATA ANALYSIS 
 
9.1 DATA ANALYSIS PLAN 
The primary analyses will be by intention to treat.  
We will use random-effects models to compare the effects of supplementation with RUSF-v and RUSF on: (i) 
the ratios of plasma arginine:ornithine and arginine:ADMA; (ii) the concentrations and enzyme activity of 
plasma arginase; and (iii) FMDmax.  Weights and heights will be converted to internal Z-scores (generated from 
data of all HbSS children in this age group) and mixed effect models used to compare rates of growth during 
periods when receiving RUSF with washout periods. The large sample size and repeated assessments of FMD 
has been planned to allow:  
• high precision in estimating outcomes; 
• power to test for effect modification on FMDmax by high vs low FMD, ADMA concentrations, arterial 
diameter and peak blood flow at baseline; 
• formal testing for a carry-over effect (not expected) by testing for an interaction between treatment 
and order of assignment. 
Further analyses will test for associations between proximal markers of vascular dysfunction and FMDmax and 
incidence/duration/severity of VOC painful episodes during the supplementation periods. Painful episodes will 
be fitted in a negative binomial model relating the number, total days, or total severity score of self-reported 
painful episodes to age, sex, baseline Hb and fetal haemoglobin percentage (HbF%).  
9.2 SAMPLE SIZE 
The sample size of 120 has more than 99% power to detect a small, but potentially clinically relevant effect size 
(∆) of 1.25 unit change in FMDmax between the treatment arms, thus even if we allow for 33% drop outs or 
incomplete data at any of the time points, we will still have more than 95% power. Similarly a sample size of 
120 has more than 99% power to detect a 20% difference in growth rates for height and weight.  
Sample size calculations were conducted using the following data (see Fig 7 for worked example).  
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1. FMDmax: The within-individual standard deviation (SD) for repeated measures over 3 months of FMDmax, 
using the same protocol, in 42 healthy British adults, is 1.04 units [41]. However, as HbSS children have a 
fluctuating disease state, we have taken a conservative approach and doubled this to 2.08. FMDmax in 18 
British HbSS children with obstructive sleep apnoea, was 7.71 (SD) 6.27 (Kirkham, unpublished data) 
compared to 6.3 (SD) 5.4 in 31 British HIV+ children treated with protease inhibitor ARVs, who had 
significantly lower FMDmax (and greater variance) compared to HIV positive children not treated with 
protease inhibitor drugs [40]. Taking a conservative approach we used the largest inter-individual SD of 
6.27.  
2. Growth rates.  The mean within-individual growth rate in 181 Tanzanian HbSS children aged 8-11y at first 
measurement, with a minimum of 8 months’ follow-up and 3 measurements is 0.377+/-0.283cm/month. 
The size of the SD compared to the mean (SD/mean = 0.75) is greater compared to Gambian children of the 
same age, collected under strict quality control conditions (SD 0.177/0.425 = 0.41).  This is likely a function 
of greater inaccuracy in single measurements conducted in a busy clinic, and genuine increased within-
individual variance due to SCD status. In Gambians, an increase of 0.5 SD translates to a 20% increase in 
growth rate, which is a clinically significant effect likely to be observed in the duration of RUSF 
supplementation in this study. Between-individual variation (SD) in growth in the HbSS children was 
0.234cm/month. Hence we based our calculations on an effect size of 0.5 x within-individual SD in 
Tanzanian HbSS children for height and weight growth rates. 
  
V-FIT Page 25 of 65 Version 1.1; 20th Jan2014 
Figure 7. Worked example of sample size calculation.  
 
 
9.3 INTERIM ANALYSES 
No interim analyses of the study endpoints are planned. The DSMB will monitor safety data, rates of 
enrolment, randomisation and trial conduct. At present the plan is to analyse the number of adverse events in 
each arm of the trial at 4 monthly intervals, unless there is a serious adverse event resulting in a death or as 
otherwise deemed necessary by the DSMB, in which case the number of adverse events in each arm of the trial 
will be assessed within 1 month.  
 
10. MONITORING 
 
10.1 RISK ASSESSMENT 
 
Based on a review of available data concerning these and similar interventions in SCD and non-SCD 
populations, this study is considered to have a low risk. As such monitoring is as outlined below.  
 
10.2 INTERNAL MONITORING AT STUDY SITE 
 
OpenClinica (https://community.openclinica.com/) will be used to manage trial data.  OpenClinica is an 
opensource clinical trials data management systems that supports both electronic data capture (EDC) and 
1.       FMDmax  
Within individual variance (sw
2) = SD2/2 =2.082/2 = 2.163
Between individual variance (sB
2)  =  SD2/2 =6.272/2 = 19.66
N= 1+R x [(1.96+1.28)/ (∆/sw)]
2      
R=reliability of measurements = sB
2/(sw
2 + sB
2).
R=19.66/(2.163 + 19.66) = 19.66/21.82= 0.9009
N= 1+R x [(1.96+1.28)/ (∆/sw)]
2
N = 1+0.9009 x [3.24/0.85]2
N=1.9009 x 14.52 = 27.6 rounded up to an equal number for randomisation = 28.
2.   Growth
An interaction effect between two orthogonal binary variables both with equally sized 
groups, requires four times the sample size required for the same sized main effect.
Sample size at 90% power and 5% significance and one sided test (height) two sided test 
(weight) is estimated from the same formula giving a sample size of N=16 for growth in 
height and N=20 for weight.
Sample size at 90% power and 5% significance for two-sided test is estimated from the 
following formula:
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paper CRFs.  OpenClinica is 21 CFR part 11 compliant and is designed to meet the ICH harmonised tripartite 
guideline. To ensure data quality and completeness, range and consistency checks will be built into OpenClinica 
and paper-based CRFs. 
 
Real-time data collection into electronic CRFs will be utilized using study-dedicated computers networked to 
the MSC intranet and server, in the cases of: (i) patient registration at clinic-study visits, to confirm the identity 
and details of the patients from the trial-specific patient demographic table and record trial visits within the 
MSC outpatient register; (ii) demographic, clinical and anthropometric data at clinic study visits and; (iii) ECG 
and ultrasound data FMD data (CRF & direct recordings from the ultrasound and ECG equipment).  Paper forms 
will be available in the event of breakdowns in the network. The advantage of real-time data entry is that the 
quality of the data being collected can be assessed immediately, with event specific instructions built-in and 
multiple “what if” options. For example, the accuracy of the anthropometric data is paramount and therefore 
observations must be made by two independent observers, which if not within a set limit of agreement, will 
result in a trigger for both observers to repeat the measurements, until agreement is reached. Range and 
consistency checks can be built-in, which can also look up data from previous visits to check for anomalies. 
To ensure continuity of study routines and data collection in the event of a system / network failure, paper 
CRFs will be used as a backup.  This will be identical to the electronic CRFs in OpenClinica allowing the seamless 
transfer of data from paper to OpenCLinica once the system is back online 
Paper records will still be used for home-visits. This is because the risk of theft of handhelds or netbooks is 
considered too high in these circumstances and the reliability/security of the mobile internet networks not 
good enough to ensure real-time, secure data transmission to the study-server. Paper records will also be used 
for recording informed consent and these will then be scanned and also saved as electronic files. 
Daily and weekly monitoring will be conducted by the trial coordinator and internal monitor (MWP Data 
coordinator) for quality assessment and control to ensure completeness and accuracy of paper and online CRFs 
with immediate follow-up of missing or extreme data points. Source document verification checks will also be 
conducted for the online CRFs by comparing to what is in the actual current database compared to separately 
stored original and corrected CRFs. 
 
10.3 EXTERNAL MONITORING AT STUDY SITE 
 
Independent Trial monitoring will be conducted by KEMRI-Kilifi Clinical Trials Facility. A total of 5-6 site visits 
by the monitoring team are planned: pre-study visit, site initiation, 2 monitoring visits at 2 and 9 months post 
start of enrolment and a trial-close out visit. At the site initiation visit final procedures will be agreed between 
the TSC & DSMB for protocol violations, any interim analyses by the DSMB, and definitions, monitoring and 
reporting procedures for adverse events. The independent trial monitoring team will check on all study 
procedures including: appropriate randomised recruitment and blinding, adherence to protocols, and 
amendments, compliance with GCP and applicable regulatory requirements, completeness and accuracy of 
data forms, appropriate storage of confidential information, and appropriate labelling and storage of serum 
samples. The following data will be validated from source documents:  
• Eligibility and signed consent 
• Random sample of anthropometric data 
• Random sample of FMD data 
• a random sample of reported laboratory results (haematology full blood pictures, clinical chemistry 
safety data, plasma amino acid concentrations) 
Reports of each site visit for monitoring will be sent to the TSC & DSMB. The DSMB will have access to 
unblinded data and will inform the TSC & sponsor if the trial should be stopped early for any reason. 
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11. REGULATORY ISSUES 
 
11.1 CTA 
Local regulatory approval for this trial is being sought from the Tanzanian Food & Drug Authority as per 
Tanzanian national requirements 
 
11.2 ETHICS APPROVAL 
Ethical approval has been obtained from the LSHTM Research Ethics Committee, as well as from the Tanzanian 
National Ethics Committee (TNEC) as per requirements for research studies in Tanzania.  Ethical approval has 
also been obtained from MUHAS Research & Publications Committee as required for research conducted by 
MUHAS. The TSC will require copies of the ethics approval letters (LSHTM, TNEC & MUHAS) before enrolling 
participants into the study.  The study will be conducted in accordance with the recommendations for 
physicians involved in research on human subjects adopted by the 18th World Medical Assembly, Helsinki 1964 
and later revisions. 
 
11.3 CONSENT  
Consent to enter the study must be sought from the parent or guardian of the child to be enrolled only after a 
full explanation has been given, an information leaflet offered in Kiswahili and English and time allowed for 
consideration. Assent from participating children will also be sought. Signed participant consent must be 
obtained (unless an individual is unable to write, in which case a thumb print is acceptable). The right of the 
parents or guardians to refuse to participate without giving reasons must be respected.  All participants are 
free to withdraw at any time from the protocol treatment without giving reasons and without prejudicing 
further treatment. Please see Appendix 6 for the Patient Information Sheet and Informed consent form.  
 
11.4 CONFIDENTIALITY 
 
Participants’ identification data will be required for the registration process. Thereafter CRFs will not use 
participant’s identification data and the study database will contain anonymised data linked to the MSC ID and 
further personal identifiers.   
 
11.5 INDEMNITY 
 
London School of Hygiene & Tropical Medicine holds Public Liability ("negligent harm") and Clinical Trial ("non-
negligent harm") insurance policies which apply to this trial. 
 
11.6 SPONSOR 
London School of Hygiene & Tropical Medicine will act as the main sponsor for this study.  Delegated 
responsibilities will be assigned locally.   
 
11.7 FUNDING 
The Wellcome Trust, UK is funding this study.  
Study participants will receive a contribution towards travel expenses on attending each of the 5 study visits at 
the research office in Muhimbili National Hospital [TSH 5,000 ≈ £2.00] 
No payments are being made to the investigators, beyond the standard LSHTM salary of the chief Investigator, 
Dr Sharon Cox for the duration of the research grant as detailed in the grant application, award letter and GRN 
budget loading form.  
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11.8 AUDITS AND INSPECTIONS  
The trial will be audited and monitored by KEMRI-Kilifi Clinical Trials facility, who will report to the TSC DSMB & 
Trial sponsor in order to ensure adherence to GCP policies as approved by the study sponsor the London School 
of Hygiene & Tropical Medicine. The trial may also be subject to audit by the Tanzanian Food and Drug 
Authority with whom the trial will be registered locally.  
Personal medical data may be reviewed by appropriately authorised individuals as part of monitoring and/or 
audit of the trial but such information will be treated as strictly confidential and will in no circumstances be 
made publicly available. Monitoring visits are scheduled as in Section 10.3.  
 
 
12. TRIAL MANAGEMENT 
12.1 TRIAL MANAGEMENT GROUP   
The Trial Management Group (TMG) consists of the CI and co-investigators as listed above on p3.  
12.2 THE TRIAL STEERING COMMITTEE  
The Trial Steering Committee (TSC) includes one independent and locally experienced member, Dr Saidi Kapiga, 
Head of Mwanza Interventions Trials Unit, Tanzania (Chair), The chief investigator (Dr Sharon Cox), Co-
investigator, Professor Fenella Kirkham and the trial statistician (to be appointed) will make up the remaining 
members of the TSC.  
12.3 DATA SAFETY MONITORING BOARD 
The DSMB consists of 4 independent experienced and suitably qualified members as per LSHTM guidelines 
(LSHTM/SOP/033 FINAL v2.0) and will operate under a charter.  Dr Trudie Lang, (University of Oxford) is the 
chair. The other members include Professor Esther Mwaikambo, (Pediatrician, Herbert Kariuki University, 
Tanzania), Dr Ramadhani Noor (African Academy of Public Health, Tanzania) and a statistician (Dr Prabin Dahal, 
University of Oxford 
 
The role of the DSMB includes the review of the implementation and progress of the study. It provides initial, 
regular, and closing advice on safety-related issues to the investigators and sponsor.  Its advice is based on the 
interpretation of study data with reference to the study protocol. The DSMB will meet before the initiation of 
the study (pre-initiation review) and 4-monthly thereafter. They will review the Protocol and Report and 
Analysis Plan (RAP). Other unscheduled meetings may be required. Meetings may be face to face or via 
teleconference. Meetings must be documented and minutes made available to the sponsors. The DSMB may, if 
deemed necessary, convene a meeting with, or request further information from the Chief Investigator or 
sponsor at any stage of the study. 
The DSMB may recommend to the sponsor to suspend the enrolment to the trial and/or interventions based 
on their review of safety data arising in this trial or other relevant trials of similar interventions. 
The DSMB will be informed of:  
• All SAEs. SAEs judged to be related or fatal will be sent to the DSMB within 24 hours.  
• SAE summary tables will be in advance of DSMB meetings (DSMB will have the allocation code to allow 
unblinding). 
• All withdrawals of study subjects by the CI or the parent(s)/guardian(s) of a subject due to adverse 
events. 
• New information that may affect adversely the safety of the subjects or the conduct of the study. 
• All subsequent protocol amendments, informed consent changes or revisions of other documents 
originally submitted for review.  
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13. PUBLICATION POLICY 
 
All publications and presentations relating to the study will be authorised by the TMG in advance.  Members of 
the TSC and the DSMB will be listed and acknowledged. Authorship of parallel studies initiated outside of the 
Trial Management Group will be according to the individuals involved in the project but must acknowledge the 
contribution of the TMG members.  
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APPENDIX 1. DETAILED RATIONALE FOR INTERVENTION 
COMPONENTS, DOSAGE & CHOICE OF VASCULAR FUNCTION 
ASSESMENT 
 
Endothelial dysfunction occurs in SCA, including in children 
Endothelial function assessed in 16 HbSS adult patients and 15 HbAA controls, using a variety of 
techniques, demonstrated increased resting wall shear stress, decreased NO-mediated vasodilatory responses 
assessed by FMD, and an absence of vasoconstriction in response to inhalation of 100% oxygen compared to 
controls [54]. Although endothelium-dependent microvascular dilatation (assessed by measuring forearm 
blood flow (FBF) response to acetylcholine using venous occlusion plethysmography) appeared to be increased, 
this was no longer apparent after adjusting for increased baseline blood flow [54]. These findings suggest 
inappropriately low NO release under basal conditions and a reduced ability of the conduit vessels to adjust 
appropriately to the rheologic condition. This situation could potentially explain an increased likelihood of 
precipitating interactions between HbSS erythrocytes and the dysfunctional endothelium, and therefore vaso-
occlusive events. FMD was decreased and inflammatory markers and soluble adhesion molecules increased in 
10 young adult SCD patients compared to matched controls and FMD further decreased during sickle cell crisis 
[55]. In  21 HbSS children, mean age 10 years, mean FMD maximum response (4 mins ischaemia of ipsilateral 
upper arm)  was 5.6% +/- 0.2%, significantly lower compared to Afro-Caribbean control children (8.0%+/-0.2%) 
P=0.008. No differences between the groups were observed for non NO-mediated response to 
glyceryltrinitrate [56].  
Justification for intervention with L-arginine (L-arg) & L-citrulline (L-cit): Metabolism, pharmacokinetics, 
nitric-oxide synthesis and vascular function 
L-arg, a semi-essential basic amino acid, is the sole substrate for eNOS. Endogenous arginine synthesis 
is insufficient in growing children [57] and deficiency is observed in malnourished children (Jahoor Am J Clin 
Nut  07). Even in the USA, it is estimated that 25% of adults consume sub-optimal intakes of less than 2.6g/d 
arginine [58]. The best dietary sources of arginine are soy protein, seeds, nuts, meats and seafood; foods not 
readily available in low-income African settings. L-cit is a non-protein amino acid, which can be synthesized in 
the gut from glutamine and proline, and importantly, is a precursor for arginine synthesis in the gut, kidneys 
and elsewhere, including endothelial cells [59].  
Oral supplementation with L-arg and L-cit greatly increases plasma arginine levels, with low urinary 
excretion, even at very high doses [60]. L-cit has higher bioavailability and longer half-life compared to L-arg, 
resulting in greater plasma arginine levels and area under the curve compared to similar doses of L-arg [53, 60], 
probably due to lower first pass metabolism in the gut and liver [61]. In conditions of inflammation and injury, 
particularly to liver parenchymal cells, arginase I is released into the plasma. Haemolysis releases arginase from 
erythrocytes. These conditions can result in arginine deficiency [62, 63].   
Limited arginine supply uncouples eNOS, producing reactive oxygen species (ROS), thus generating a 
positive feedback loop of oxidative stress, increased haemolysis, release of arginase and further endothelial 
dysfunction including increased adherence of platelets and leukocytes. Plasma haemoglobin (p-Hb), which is 
increased in SCD, is a potent scavenger of NO [64] and is associated with endothelial dysfunction in animal 
models of acute haemolysis [65], although the level of contribution of p-Hb in SCD to NO bioavailability has 
recently been questioned [66].  
Arginine and arginine metabolites in vascular function in non-SCA populations  
High plasma concentrations of the methylated arginine metabolite, asymmetric dimethylated arginine 
(ADMA), an endogenous inhibitor of eNOS, and low ratios of arginine to ADMA predict cardiovascular risk and 
disease progression in a number of conditions associated with endothelial dysfunction including type 2 
diabetes [67], peripheral arterial disease [68], malaria [69] and chronic heart failure [70] and in the general 
population [71, 72]. Increased ADMA concentrations are the only significant predictor of lower FMD 
measurements in healthy black European men compared to matched whites [73].   
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ADMA is thought to be produced in response to breakdown of arginine-containing proteins during 
inflammation and is not cleared by the kidney efficiently, but is degraded by dimethylarginine 
demethylaminohydrolases (DDAH) expressed in the vascular endothelium and cardiomyocytes. In an 
atherosclerotic mouse model, over expression of DDAH decreased levels of ADMA and improved vascular 
function [74], whilst polymorphisms in DDAH have been associated with arterial disease severity in diabetes 
[75], suggesting that ADMA is causally associated with vascular dysfunction.  
Global arginine bioavailability ratio (arginine:ornithine+citrulline), independently of ADMA, predicted 
major adverse cardiovascular events in a community based follow up of a healthy older population [76].   
Clinical trials of L-arginine or L-citrulline in relation to vascular function and disease 
Clinical trials of short-term (parenteral and oral, 1-7 days) and longer-term supplemention with L-arg, 
and a few with L-cit, have shown significant effects on measures of vascular function and associated markers. 
Most have been short-term studies in subjects with disease states including diabetes [77, 78] malaria [79], 
stable coronary heart disease or hypercholesterolaemia [80, 81].  In a randomised, cross-over clinical trial in 20 
healthy volunteers with ADMA concentrations in the highest quartile of the normal range , oral L-cit and L-arg 
supplementation for 1 week (L-cit max 6g/day [approx. 0.1g/kg/day], L-arg max 3.2 g/day [0.05g/kg/day]), 
significantly increased plasma arginine concentrations and the ratio of plasma arginine to ADMA [53]. L-
citrulline supplementation increased the area-under the curve (AUC) 2-3 times more than similar doses of L-
arginine [53]. The max dose of L-citrulline also significantly increased markers of NO production and NO 
bioactivity (urinary nitrate and cGMP) [53]. None of the treatments in this study resulted in significant changes 
in FMD60, (measured at 60 seconds peak reactive hyperaemia). However, when data from all the treatments 
were combined a significant correlation was observed between an increase in arginine:ADMA ratio and 
increased FMD. As these were healthy volunteers, FMD at baseline was normal (6.9% +/-1%) and therefore 
effects may have been limited to those with vascular function at the lower end of the range or those with the 
lowest arginine:ADMA ratios, which was not formally tested [53]. A recent meta-analysis assessing the effect of 
short term L-arginine supplementation on endothelial function assessed by FMD, in a range of population 
groups, concluded that it was effective when baseline FMD measures were low (<7%) [82]. The one long-term 
trial of L-arg (3g/day, 6 months) [83] in adults with intermittent claudication, showed increased plasma arginine 
but failed to show an effect on the primary outcome of absolute claudication distance (ACD) whilst FMD 
decreased in the L-arg arm. This is in contrast to similar short-term trials in patients with the same disease 
condition in which ACD and FMD improved [84] [85]. In the trial by Wilson and colleagues [83] functional 
capacity improved in both arms from baseline. Tolerance to long-term L-arg supplementation was suggested as 
the possible cause. Alternatively, arginase activity could be up-regulated, resulting in increased ornithine 
available for synthesis of polyamines and proline, which may encourage vascular remodelling, increasing 
stiffness and ability to respond to vasodilatory stimuli [86]. Hence we propose to measure FMD in a subset of 
patients at intermediate time points in the supplementary period, whilst this further justifies the strategy of 
combining a potential arginase inhibitor with L-arg supplementation.  
Arginine and arginine metabolites in SCD 
In American adult SCD patients, low ratios of plasma arginine to ornithine were associated with high 
plasma arginase activity, increased tricuspid rejurgitant jet velocities (TRV - a predictor of pulmonary 
hypertension (PH) in this population) and death [21]. Low ratios of L-arg:ADMA have also been observed in SCD 
[87, 88] and strongly associated with TRV and death [24, 25]]. 
In mice models of SCA, arginine supplementation lowers oxidant stress markers, increases NO 
metabolites [89] decreases, p-Hb and increases microvascular function [90]. There are limited published studies 
of oral L-arg or L-cit supplementation in SCD. The addition of single dose  L-arg  to patients stabilised on 
hydroxyurea (HU), resulted in increases in metabolite markers of NO production for all patients, supporting the 
hypothesis that HU induces NOS as well as increasing HbF levels, but is dependent on available arginine [91]. 
Five days of oral supplementation (0.1g/kg/day in 3 divided doses) in 10 SCD patients with PH diagnosed by 
echocardiography resulted in a significant decrease in TRV and increased plasma arginine [51]. In the one long-
term (12 week), open label-phase I-II trial of L-arg in SCD, (0.1-0.2g/kg/d in 3 divided doses) vs. sildenafil in 
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adults stabilised on HU therapy, L-arg had no effect on TRV or on 6 minute walk distances (n=11), which 
improved in the sildenafil group (n=13) [50], although the use of sildenafil may be limited by increased pain. In 
addition, this study is seriously compromised by its small sample and significant imbalances in baseline 
characteristics, with patients in the sildenafil group having significantly worse TRV at baseline. An even smaller 
study of 4 weeks L-citrulline (0.1g/kg/day, 2 divided doses) in 5 SCD adolescent patients, resulted in 
significantly increased plasma arginine and decreased white cell counts compared to baseline. Patient self-
assessment of well-being using a visual analogue scale also increased [52].  A definitive trial is required. 
Dosage of L-arginine and L-citrulline 
 The final targeted dosages of the amino acids (0.2g/kg/d for L-arginine plus 0.1g/kg/d for L-citrulline) 
were chosen on the basis of three criteria: 1) safety; 2) evidence of efficacy; and 3) limitations on the amounts 
that can be incorporated into the RUSF, whist maintaining sufficiently high energy-density, taste and textural 
properties.  
The observed safe level (OSL) for L-arginine is 20g/day in healthy adults (please see below). This is 
equivalent to 0.33g/kg/d assuming an average adult weight of 60kg. Doses of 0.1-0.2g/kg/day of L-arginine [50, 
51] & L- citrulline [52] have been utilized previously in SCD subjects with no adverse effects or toxicities 
reported and resulted in significant increases in plasma arginine concentrations. Three months’ L-arginine 
supplementation (0.1-0.2g/kg/d) increased plasma arginine over time from baseline (50.1+/-17.0 µMol/L, N=8) 
to a near 100% increase at 12 weeks [50].  
A lower dose of L-citrulline compared to L-arginine is proposed based on: i) doubled or greater AUC 
plasma arginine responses compared to L-arginine [53]; ii) relative expense of L-citrulline compared to L-
arginine; and iii) less evidence available to determine observed safe levels.  
Justification for use of chloroquine: inhibition of arginase-I and anti-inflammatory properties 
 Chloroquine (CQ) is used as an anti-inflammatory drug in rheumatoid arthritis and lupus as well as an 
anti-malarial. CQ has been shown in vitro, to competitively inhibit arginase, at physiological pH and micromolar 
levels [92]. Thus in addition to anti-inflammatory effects through immune-modulation, CQ may increase NO 
bioavailability, by competitive inhibition of arginase in the plasma, endothelium and potentially in the liver.  
 In rheumatoid arthritis, daily doses in adults of 4mg CQ base/kg are used to achieve plasma CQ 
concentrations of around 1 µMolar, although there are reports of large inter-individual variability in steady 
state values [93], whilst 10-14-fold higher CQ concentrations occur in red cells and leukocytes [94]. Allowing for 
plasma protein binding compared to the in-vitro model using 10% serum, we estimate that plasma 
concentrations of 1 µMolar will achieve a meaningful reduction in plasma arginase activity. We do not know 
what CQ concentration may be reached in the vascular endothelium and smooth muscle cells and therefore 
what levels of arginase inhibition.  
 Evidence from in-vitro and animal models supports the hypothesis that inhibition of arginase can 
increase NO bioavailability and vascular function: firstly, blood vessel arginase activity is associated with in vitro 
levels of NO production [95]; secondly, pre-treatment of rats with the synthetic arginase inhibitor Nw-hydroxy-
nor-L-arginine (nor-NOHA) reduces liver ischaemic reperfusion injury by preventing the rapid drop in L-arg  and 
reduces liver necrosis [63]; thirdly, nor-NOHA treatment prevents the development of hypertension and 
improves aortic endothelial function via a NO-dependent mechanism in pre-hypertensive and young 
spontaneously hypertensive rats [96], and significantly reduces blood pressure and improves endothelial 
function in already hypertensive rats to levels comparable to normal rats [97, 98].  
 Weekly CQ as an anti-malarial is currently recommended by Tanzanian government guidelines. 
However, due to possible resistance to CQ, alternative anti-malarial prophylactics are being discussed 
(although there are no obvious choices for affordable, safe, effective and life-long use in this setting). It is also 
importnatn to consider the very different malaria transmission levels within a country like Tanzania, with urban 
Dar-es-Salaam experiencing low transmission levels, particularly in SCD patients [99]. In the light of this on-
going policy debate it is potentially important to evaluate possible additional benefits of CQ use (we plan to 
assess levels of CQ resistance as part of separate research project using archived samples). 
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Justification of flow mediated dilatation to assess vascular function 
 The principle vascular research question is whether the RUSFv intervention will improve the 
bioavailability of NO in the arterial wall.  The gold standard method of addressing this question is to analyse 
basal vascular tone and vasomotor responses to endothelium-dependent stimuli by venous occlusion 
plethysmography with and without intra-arterial administration of the NO inhibitor L-NG monomethyl arginine.  
This approach would require multiple arterial punctures with prolonged invasive analysis of forearm vascular 
function, which would not be clinically or ethically appropriate in a paediatric study of this size. 
A more suitable alternative approach is non-invasive assessment of flow-mediated dilatation (FMD) of 
the brachial artery. This technique uses well validated methodology to measure the vasodilatation of the 
conduit artery supplying the forearm in response to a reactive hyperaemic stimulus.  Local inhibiton of nitric 
oxide synthase with LNMMA at doses that did not affect systemic haemodynamics have shown that FMD 
response is predominantly, if not entirely NO-dependent [100-104]. Other non-invasive techniques for 
assessing endothelial function are less reproducible in children [105] or only partially nitric oxide dependent 
[106].  EndoPAT has been proposed as a potential means of assessing endothelial function in children with 
sickle cell disease [107]. However, it has not been fully validated in children and requires a new set of finger 
probes for each study at a substantial cost.   
Non-invasive assessment of reactive hyperaemic response could also be an informative outcome 
measure. This can be measured using venous occlusion plethysmography, but can also be determined during 
the FMD protocol by measuring brachial artery blood flow at baseline and throughout reactive hyperaemia 
using pulse wave Doppler. We will consider this response as a secondary vascular outcome as it is only partially 
NO-dependent and previous studies of short-term L-arginine supplementation in other conditions have not 
consistently affected the magnitude of reactive hyperaemia [108, 109]. 
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APPENDIX 2. EXAMPLE LIST OF EXPECTED TOXICITIES & POTENTIAL DRUG INTERACTIONS 
 
Toxicity* Chloroquine* Notes for Chloroquine L-Arginine & L-Citrulline 
supplemented RUSF 
Notes L-Arg & L-Cit  
General     
Headache ✓    
Haematopoeitic     
bone marrow depression, including aplastic anaemia, 
agranulocytosis, thrombocytopenia, neutropenia  
✓ rare   
Hepatic     
Changes in liver function, hepatitis and abnormal liver function tests ✓ rare   
Hypersensitivity     
Allergic and anaphylactic reactions ✓ rare   
urticaria ✓ rare   
Angiodema  ✓ Rare    
Gastrointestinal     
Abdominal cramps ✓  ✓ Sometimes reported at 
high doses >9g/kg/day 
Vomiting,  ✓    
Diarrhoea ✓  ✓ Sometimes reported at 
high doses >9g/kg/day 
Nausea  ✓    
Cardiovascular      
Cardiomyopathy  ✓ Reported rarely at long 
term therapy at high 
doses 
  
Cardiac dysrhythmias  ✓ Can occur at high doses   
hypotension ✓    
Central Nervous system ✓    
Seizures  ✓    
Convulsions  ✓ Reported rarely may 
result from cerebral 
malaria – give injections 
of phenobarbitol 
  
Psychiatric disorders – anxiety, confusion, hallucinations, delirium ✓    
Eye disorders      
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Transient blurred vision & reversible corneal opacity ✓    
Retinopathy ✓    
Irreversible retinal damage  ✓ Rarely reported at long-
term high dosage 
  
Macular defects of colour vision, optic atrophy, scotomas, field 
defects, blindness & pigmented deposits, difficulty in focussing & 
diplopia 
✓    
Muscular     
neuropthy ✓    
myopathy ✓    
Skin     
skin eruptions, pruritis, depigmentation, loss of hair, exacerbation 
of psoriasis &  photosensitivity 
✓    
Pigmentation of nails & mucosae ✓ Rarely reported at  long-
term high dosage 
  
Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal 
necrolysis, exfoliative dermatitis and similar desquamation-type 
events 
✓ Rarely reported   
 
* taken from the Summary of product characteristics (SPC) CQ-sulphate – Nivaquine 
 (http://www.medicines.org.uk/EMC/medicine/2272/SPC/Nivaquine/) accessed 23/09/2011. 
 
Concomittant use of CQ should be avoided with the following drugs: (taken from British National Formulary 61, March 2011) 
• Amiodarone (anti-arrhythymic drug) – increased risk of ventricular arrhythmia  
• Moxifloxacin (antibiotic) -  increased risk of ventricular arrhythmia 
• Droperidol (antipsychotic) - increased risk of ventricular arrhythmia 
• Antiepileptics  - possible increased risk of convulsions 
• Mefloquine  (antimalarial) - increased risk of convulsions.  
Other known drug interactions 
• Antacids reduce absorption of CQ 
• Digoxin – CQ increases plasma concentrations of digoxin 
• Ciclosporin (immune-suppressant) - CQ increases plasma concentrations of ciclosporin and therefore potential toxicity 
• Cimetedine – (ulcer healing) affects metabolism of CQ resulting in increased plasma concentrations 
• Lanthanum (renal failure) reduces absorption of CQ 
• Laronidase (enzyme replacement for mucopolysaccharidosis) – CQ possibly inhibits effects of laronidase (manufacturers recommendation) 
• Histamine (anti-inflammatory) – antimalarials to be avoided, recommended by manufacturer of histamine 
• Neostigmine & Pyridostigmine (parasympathomimetics) CQ potential to increases symptoms of myasthenia gravis and therefore reduce effects of these drugs 
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APPENDIX 3. SUMMARY OF INVESTIGATIONS, TREATMENT AND ASSESSMENTS 
 
Table A1: Investigations and assessments for all study participants at clinic-study visits.  
 
Exam Month of follow up 
 Pre-treatment 4 8 12 16 
Informed consent X X X X X 
History, physical exam X X X X X 
Anthropometry X X X X X 
Brachial FMD by ultrasound X X X X X 
5ml blood sample – FBC, 
clinical chemistry panel and 
serum/plasma archiving 
X X X X X 
 
Please see draft V-FIT CRFs#1, 2 & 3 
 
All participants will also have data collected in V-FIT CRF#-4 home visits at bi-weekly home visits and telephone interviews in the intervening 
weeks by a study field worker.  
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APPENDIX 4. EXPECTED ADVERSE EVENTS IN THIS STUDY 
 
Table A4a: Expected Adverse Events 
 
Expected AE's Expected AE's Expected AE's 
Abnormal haematology/clinical 
chemistry tests† Hemiplegia Pulmonary embolism 
Acute chest syndrome Hepatosplenomegaly Pulmonary hypertension 
Anaemia HIV-infection Pyelonephritis  
Aplastic crisis/anaemia Hyperplastic bone marrow  Renal insufficiency/albuminuria 
Avascular necrosis of femoral head Hyposthenuria Reticulocytosis (10%–20%) 
Avascular necrosis of hip/shoulder Hypoxaemia (SpO2<96%) Retinal haemorrhage 
Bone infarction Infection, pneumococcal  Retinopathy* 
Bruising Infiltrates on chest x-ray Rhabdomyolysis 
Cardiomegaly Jaundice Sepsis 
Cholecystitis, hepatic sequestration Leukocytosis Seizures* 
Cranial nerve palsy LRTI Silent cerebral infarct 
Dactylitis Macular defects* Skin disorders pruritis, depigmentation* 
Decreased kidney function Malaria Skin ulcers 
Decreased lung function Meningitis Splenic sequestration 
Delayed growth Overt Stroke TB infection 
Fever Pain, joint Transient Ischaemic attack 
Haematuria Pain, long bone Urinary tract infection 
Haemolysis Pain, severe abdominal URTI 
Hair loss Priapism Urticaria* 
Headache Psychiatric disorders* Wind** 
 
† Significant deviations from normal steady-state values for sickle children aged 8-11 when free of symptoms (See Appendix 4b) 
*AE that could be associated to CQ intervention 
**AE that could be associated with the RUSFv intervention 
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For reporting purposes AE’s will be categorised according to the following headings (Table 4b) with more information given as available.  
 
Table 4b.  
ADVERSE EVENT  code  ADVERSE EVENT  code  ADVERSE EVENT  code  
Acute Abdomen/Obstruction/Helminthiasis 1 Fever with source 12 Priapism 23 
Acute anaemia  2 Fever without source 13 Psychiatric (all types) 24 
Acute chest syndrome 3 Gastro-enteritis 14 Sepsis 25 
Asthma 4 Hepatitis 15 Seizures 26 
Cardiac/pulmonary problems (non-congenital) 5 Leg ulcers 16 Splenic sequestration 27 
Cellulitis/Pyomiositis/abscess 6 LRTI 17 Stroke 28 
Dactylitis  7 Malaria 18 TB infection - all types 29 
Encephalopathy- unknown 8 Meningitis 19 URTI 30 
Epilepsy 9 New avascular necrosis 20 Urinary tract infetction 31 
Eye/vision problems 10 Osteomyelitis 21 Vaso-occlusive pain 32 
Febrile convulsions 11 Pneumonia 22 OTHER 33 
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Table A4c: Grading of Laboratory Adverse Events 
 
 LABORATORY EVENTS 
PARAMETER GRADE 1 
MILD 
GRADE 2 
MODERATE 
GRADE 3 
SEVERE 
GRADE 4 
POTENTIALLY 
LIFE-THREATENING 
HAEMATOLOGY ULN = Upper Limits of Normal  
(steady state values in Tanzanian SCA children aged 8-11.9y = mean +2 x SD)* 
Hemoglobin any decrease  1.0 
g/dL from baseline  
any decrease  2.0 
g/dL from baseline 
any decrease  2.5 g/dL 
from baseline 
any decrease  3 g/dL 
OR 
< 4g/dl 
WBC 103/mm3  Elevated 
WBC 103/mm3 -Decreased 
1.1– 1.3 x ULN 1.4 – 1.8 x ULN 1.9 – 2.5 x ULN > 2.5 x ULN 
0.9-1.0 x LLN 0.75-0.9 x LLN 0.5-0.75 x LLN <0.5 x LLN 
Neutrophil % 1.1– 1.3 x ULN 1.4 – 1.8 x ULN 1.9 – 2.5 x ULN > 2.5 x ULN 
Lymphocyte % 1.1– 1.3 x ULN 1.4 – 1.8 x ULN 1.9 – 2.5 x ULN > 2.5 x ULN 
Platelets—Decreased 
Platelets—Elevated 
1.1– 1.3 x ULN 1.4 – 1.8 x ULN 1.9 – 2.5 x ULN > 2.5 x ULN 
0.9-1.0 x LLN 0.75-0.9 x LLN 0.5-0.75 x LLN <0.5 x LLN 
CHEMISTRIES   
 
Creatinine 1.1 – 1.3 x ULN 1.4 – 1.8 x ULN 1.9 – 2.5 x ULN > 2.5 x ULN 
AST  1.1 – 3.0 x ULN 3.1 – 6.0 x ULN 6.1 – 10.0 x ULN > 10.0 x ULN 
ALP 1.1 – 3.0 x ULN 3.1 – 6.0 x ULN 6.1 – 10.0 x ULN > 10.0 x ULN 
Bilirubin total  1.1 – 3.0 x ULN 3.1 – 6.0 x ULN 6.1 – 10.0 x ULN > 10.0 x ULN 
Bilirubin conjugated 1.1– 3.0 x ULN 3.1 – 6.0 x ULN 6.1 – 10.0 x ULN > 10.0 x ULN 
Bilrubin non-conjugated 1.1 – 3.0 x ULN 3.1 – 6.0 x ULN 6.1 – 10.0 x ULN > 10.0 x ULN 
LDH 1.1 – 3.0 x ULN 3.1 – 6.0 x ULN 6.1 – 10.0 x ULN > 10.0 x ULN 
 
V-FIT Page 44 of 65 Version 1.1; 20th Jan2014 
*Normal steady state reference ranges for clinical chemistry in Tanzanian children with SCD aged 8-11.9 years. 
 
 Mean (SD) ULN (Mean + 
2SD) 
LLN (Mean – 
2SD) 
WBC 103/mm3*  Females 
                           Males 
13.9 (4.25) 
14.6 (4.06) 
22.4 
22.7 
5.4 
6.5 
Neutrophils %* 44.0 (8.7) 61.0  
Lymphocyte %*  Females 
                              Males 
45.0 (10.5) 
43.8 (10.1) 
66.0 
64.0 
 
Platelets 103/mm3* 447 (176) 799 94 
Createnineˆ 36.8 (10.0) 56.8  
Aspartate transaminase (IU)† 42 (9) 60  
Alkaline phosphatise (IU)† 173 (41) 255  
Lactate dehydrogenase (IU)† 523 (110) 743  
Total Bilirubin (µmol/L)† 52 (28) 108  
Conjugated bilirubin (µmol/L)† 13 (3) 19  
Non-conjugated bilirubin (µmol/L)† 40 (29) 98  
*Based on measurements in 602 Tanzanian children with SCD with an average of 3 measurements each, aged 8-11.9Y at time of analysis whilst in steady state 
defined as as no malaria parasitaemia, recorded temperature <37.5°C, reported pain or hospitalization within 30 days of assessment (before or after). 
ˆBased on measurements in 512 children with SCD with an average of <2 measurements each, aged 8-11.9Yat time of analysis whilst in steady state, defined as 
above 
†Based on averaged multiple steady state measurements in 35 children Tanzanian SCD aged 8-11.9Y at the time of assessment and at steady state as defined 
above 
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APPENDIX 5. FLOWCHART FOR SAFETY REPORTING 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 AE 
observed 
 
 
 
 Is it serious?  
 
 
 Yes  No  
 
 
 Is it expected?  AE. It does not require expedited 
reporting.  Describe on CRFs 
 
 
 
 Yes  No  
 
 
SAE.  Assess for severity, 
complete SAE form and 
report to CI within 24 hrs  
 Is it reasonably, causally related 
to the study intervention  
 
 
 
Fatal?  Yes  No 
 
 
Yes  No 
 SUSAR.  Report 
to CI within 24h   
 SAE.  Assess for severity, 
complete SAE form and 
report to CI within 24h 
Bi-annual safety report  
Requires expedited 
reporting to 
TFDA/TNEC within 
24h 
   Report to 
TFDA/TNEC within 
14 days 
    
 Life-threatening 
or fatal? 
 Fatal? 
 
 
 Yes  No   Yes 
 
 
 Requires expedited reporting to 
TFDA/TNEC  
 within 24 hrs  & LSHTM within 7 days 
 Report to 
LSHTM/TFDA/TNEC 
 within 14d 
   Requires expedited 
reporting to 
TFDA/TNEC within 24h 
 
TFDA Tanzania Food and Drug authority = local regulatory authority for clinical trials 
TNEC: Tanzania National Ethics Committee 
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APPENDIX 6.   PATIENT INFORMATION AND INFORMED CONSENT FORM 
[V1.1 15.05.2012] 
 
 
            MUHIMBILI UNIVERSITY OF HEALTH & ALLIED SCIENCES 
P.O Box 65001 Dar es Salaam. Tanzania 
 
INFORMED CONSENT FORM  
Site name Site number Serial number (site specific) Study ID 
MUHAS N/A       
 
STUDY TITLE 
Vascular Function Intervention Trial (V-FIT) in Sickle cell disease 
 
THE RESEARCHERS 
This research is being conducted in collaboration with investigators from the UK and the researchers in the 
Muhimbili Sickle Cohort study in which you have already agreed to be enrolled in (please see details below).  
 
PURPOSE OF STUDY 
From the results of the research we have conducted so far, we have evidence to suggest that a food 
supplement might have beneficial effects on sickle cell disease. We have found that many children with SCD 
are malnourished and therefore are often short and thin compared to Tanzanian children of the same age 
without SCD. Poor growth is associated with poor health outcomes in many diseases including in SCD. We have 
also seen that blood levels of some nutritional factors are much lower in individuals with severe compared to 
mild SCD disease. Levels of these factors are thought to be important in maintaining the function of the vessels 
that carry our blood. We know that if these vessels do not function well in SCD, it can contribute to some of the 
symptoms and long-term effects of SCD. Also, we think that the chloroquine we have been prescribing as an 
anti-malarial prophylaxis may also have beneficial effects on blood vessel function, but we are not sure how 
much is needed for this effect. 
 
Food supplements are being used in Tanzania to treat and prevent malnutrition. We do not know if a similar 
food supplement, containing necessary vitamins and minerals, will improve growth and other outcomes in 
children with SCD, such as reducing the severity of the anemia (lack of blood). We would also like to find out if 
adding higher levels of particular nutritional factors to the same food supplement and giving lower but more 
frequent (daily) amounts of chloroquine can improve the function of blood vessels in SCD. To find out, we need 
to compare the growth and blood vessel function of children after periods of no food supplement and normal 
compared when taking a standard food supplement and when taking the food supplement with the extra 
nutritional factors added and the different chloroquine dosing from normal.  
 
We think that many SCD children are experiencing more episodes of pain and illness than we are able to see by 
only collecting information during admissions to Muhimbili National Hospital. We also think that the food 
supplements may affect painful crises experienced by SCD children. To find this out we need to be able to 
measure these accurately. Therefore we want to collect detailed information on how often children experience 
painful crises and fever by asking families to help us in recording this information and by telephoning and 
visiting children and families at home.  
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WHO WILL BE IN THE STUDY 
We are inviting children aged between 8-11 years who are already participating in the Muhimbili Sickle Cohort 
and who are permanently resident in urban Dar-es-Salaam to be included in this study. Children with pre-
existing conditions, like epilepsy or using some kinds of drugs will also not be included in this study. 
 
WHAT PARTICIPATION INVOLVES 
To answer all these questions, children will receive one of the two food supplements at the beginning of the 
study for 4 months, followed by 4 months with no food supplement, another 4 month period with the different 
food supplement and a final 4 months with no food supplement, for a total study period of 16 months. Neither 
the investigators, or you or your child will know which supplement is which, until after the study is completed. 
All children enrolled in this study will receive home visits by a study worker every 2 weeks throughout the study 
period, who will deliver the food supplement and chloroquine syrup. In the intervening weeks the field worker 
will telephone you.    
  
If you agree to participate in this study your child will be randomly allocated, to receive either the standard 
food supplement or the enhanced food supplement first.   
 
o During the study period, children should not take additional vitamin and mineral supplements unless 
recommended by a Doctor, who should be informed if your child is taking one of the food supplements at the 
time.  
o During the periods when children are NOT receiving the food supplement, children should take their normal 
folate supplements. Folate is not required when children are receiving the food supplements as the required 
folate is included within the food supplement already.  
 
1 MIEZI MINNE 2 MIEZI MINNE 3 MIEZI MINNE 4 MIEZI MINNE 5
KIPINDI  1 BILA KITU  1 KIPINDI 2 BILA KITU 2 
VIRUTUBISHO LISHE-1 VIRUTUBISHO LISHE-1
AU AU
VIRUTUBISHO LISHE-2 VIRUTUBISHO LISHE-2
HUDHURIO LA KLINIKI
MIEZI KUMI NA SITA
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Procedures at clinic visits 
Children enrolled in this study will have 5 study-specific clinic visits; at the start of the study then 4, 8 12 & 16 
months later at the end of the study. These will replace your normal sickle clinic visits, so that extra visits are 
not required. At each of these study visits the following tests or measurements will be conducted.  
o Blood samples will be collected (5ml - teaspoon) as at normal sickle clinics.  
o Children’s height and weight will be measured plus their amount of fat and muscle, measured using a new 
piece of equipment on which your child stands on the machine and holds the handles for 1 minute.  
o Blood vessel function will be measured at only the first 4 visits using a machine that uses sound to take 
pictures of the inside of our bodies – the same as we use to check on the babies of women who are 
pregnant and also similar to what we use when we have measured the speed of blood travelling inside 
blood vessels in the brain which we call “TCD”. Your child may already have had TCD done as a part of 
previous SCD research, and which is done routinely in SCD centres in other parts of the world.  We will 
measure the function of a large blood vessel in the arm and to do this, we will take pictures during the 
inflation and release of a pressure cuff, just like we use to measure blood pressure when your child comes 
to SCD clinics. The only difference is that the cuff will remain inflated for a bit longer (5 minutes) than 
normal. Finally we will also take pictures of the blood vessel before and 5 minutes after giving a small dose 
of drug (glyceryl-trinitrate) dissolved under the tongue. This drug is completely safe and is used in larger 
amounts to improve blood vessel and heart function in patients with damaged hearts and blood vessels.  
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Home visits and parents involvement in data collection 
o Families will be asked to complete a simple picture diary recording when children experience a painful 
episode, its duration and a ranking of how severe the pain as evaluated by the child and what pain 
medication, if any, was used.  
You can discuss any difficulties or worries you may be experiencing in the study during home visits and we will 
try to ensure you see the same study worker each time.  
The home visits are an important part of this study and your participation is crucial. We think we can learn a 
lot about SCD by hearing about your experiences as parents, outside of the formal hospital environment.  
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How will the blood samples collected at study clinics be used? 
We will collect only one blood sample at the study clinic visits. The normal tests that are done at the routine 
sickle clinics will be performed (full blood picture) and malaria test if required. The rest of the sample will be 
used to measure the specific factors involved in blood vessel function. Some of these measurements will be 
done in the sickle cell laboratory in Muhimbili and some will be need to be done in laboratories in the UK. Any 
left-over sample will be stored long-term for possible future studies related to increasing our understanding of 
sickle cell disease. This is the same as is happening to samples collected during normal sickle clinics.   
 
BENEFITS OF THE STUDY 
There will be no direct or financial benefits to participation in this study. Your participation will mean that we 
will find out if a food supplement and daily compared to weekly chloroquine is of significant benefit to patients 
with SCD. Although this is a food supplement and chloroquine is already used in SCD patients, it is still very 
important that we have proof that it is of benefit, safe and is acceptable to families.  
 
POTENTIAL RISKS OF THE STUDY 
o There is a very small risk of children having an allergic reaction to the food supplements. We will minimize 
this risk by giving a small test amount of the supplement while at the study clinic.  
o The volume of blood collected is small and only slightly more than is normally collected at the sickle clinics 
and will not affect the health of your child.  
o Some children may find the pressure cuff uncomfortable while it is inflated and there is a possible risk that 
your child may experience some pain after its release, although we have never observed this to happen. We 
will minimize this risk be ensuring that your child is warm and we will ask you and your child to remain 
resting in a comfortable place we will provide, for an hour after completing the blood vessel function 
measurement to make sure that no symptoms are experienced or are managed with appropriate pain relief.  
o As with any drug, there is a small risk that your child may experience some adverse effects associated with 
the use of chloroquine, either the weekly or daily doses. The majority of such effects are short-lived and 
non-serious, but we will be monitoring all these events and ask you to report any symptoms or concerns 
during the weekly clinic visits or to call the SCD patient hotline.  
 
FREEDOM TO PARTICIPATE IN THE STUDY 
We would like to stress that your participation in this study is strictly voluntary. It is your decision. Should you 
decide not to participate; it will NOT affect the treatment or management that you will receive from the 
hospital, or your participation in the ongoing cohort. In addition, you are free to withdraw your participation in 
this study (and also if you wish, the ongoing cohort study) at any point and would be effective immediately. If it 
is your wish for us to destroy any stored samples we have, we will do so.  Any such decision will be respected 
and will not influence the quality of health care we will give you or your child.  
 
CONFIDENTIALITY 
All the information that is obtained from your child and family will be confidential and in addition to using your 
current SCD no, a new study number will also be given. Only the principal researcher or somebody authorized 
by him or her will be able to link personal information back to study participants.  
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RESEARCHERS 
Dr Sharon Cox (London School of Hygiene & Tropical Medicine, UK) 
Dr Julie Makani (Muhimbili University of Health & Allied Sciences, Tanzania) 
Professor Charles Newton (UCL-Institute of Child Health, UK & KEMRI-Kilifi, Kenya) 
Professor Fenella Kirkham (UCL-Institute of Child Health, UK) 
Professor Andrew Prentice (London School of Hygiene & Tropical Medicine, UK) 
Professor Julian Halcox (University of Cardiff, UK) 
 
Please feel free to ask any questions about the information you have just been given or anything else to do 
with SCD and the care of your child. We are happy to provide you with more detailed written information 
concerning the composition of the different food supplements and the chloroquine doses at your request 
(available in English).  
 
There is more information in the form of leaflets and published papers that are available for you to learn more 
about SCD. THE SICKLE CELL FOUNDATION OF TANZANIA also has independent information on sickle cell 
disease and they would be pleased to hear from you any worries or questions you may have (please ask for 
contact details.) 
 
Please feel free to take this home with you and you can contact us or ask us during your next visit for more 
information.  
 
For the study, we will ask you to sign this paper to confirm that you have received this information and that you 
consent to participate in this study.  
 
In case there is any further information that you require with regard to the study please ask to speak to Dr J 
Makani, Department of Haematology and Blood Transfusion, Muhimbili University of Health & Allied Sciences 
(MUHAS). Tel: 0754 381551 or any of the other investigators. If you ever have questions about your rights as a 
participant, you may call the chairman of MUHAS Research and Publications Committee, P. O. Box 65001. Tel: 
2150302. 
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MUHIMBILI UNIVERSITY OF HEALTH & ALLIED SCIENCES 
P.O Box 65001 Dar es Salaam. Tanzania 
 
INFORMED CONSENT FORM 
 
Site name Site number Serial number (site specific) Study ID 
MUHAS NA       
Vascular Function Intervention Trial (V-FIT) in Sickle cell disease 
Informed consent for participants:  
I have read or I have been read the attached information regarding the SCD study in English / Swahili (please 
circle one), a language I speak fluently. I have also had an opportunity to discuss the study and ask questions to 
the investigators and I am satisfied that I understand what the study involves and my questions answered.  
 
I agree to or allow my child (listed below) to take part in this study:  
(1)_________________________________  
 
Patients/ Parent / Guardian’s  
Signature or thumb print ________________________ Date___________________ 
 
Parent / Guardian’s Name: _______________________________________________ 
(Please print name) 
Witness  
Signature (if caretaker cannot read)_________________________Date____________ 
 
Witness’ Name: _______________________________________________ 
(Please print name) 
 
I certify that the above was explained verbally to the parent/guardian, and that s/he understands the nature 
and the purpose of the study and consents to the participation in the study of the above patients.  
 
I have given them the opportunity to ask questions which have been answered satisfactorily.  
 
Research Officer 
Signature _______________________________________ Date___________________ 
 
Research Officer Name: _______________________________________________ 
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MUHIMBILI UNIVERSITY OF HEALTH & ALLIED SCIENCES 
P.O Box 65001 Dar es Salaam. Tanzania 
 
INFORMED ASSENT FORM 
 
Site name Site number Serial number (site specific) Participant number 
MUHAS N/A       
STUDY TITLE:               Vascular function trial (V-FIT) in Sickle Cell Disease 
 
THE STUDY 
We do not know if a food supplement, or a “super-food supplement” with extra ingredients, can improve 
growth and reduce the effects of SCD in children like you with SCD.  Children with SCD are often recommended 
to take chloroquine (CQ) pill or syrup once a week to protect them from getting malaria. We do not know if 
taking a smaller amount of CQ every day instead of once a week, can have more of a good effect in SCD; other 
than stopping you from getting malaria. To find out answers to these questions, we need to compare how fast 
children grow (changes in height, weight over time) and to take pictures of the vessels that carry blood, when 
children are not taking any food supplement, and when children are taking a normal, or a super-food 
supplement.  
 
If you take part in this study you will be given one of the food supplements and daily chloroquine syrup. When 
that one has finished, and you have had some time without it, you will be given the other, different, food 
supplement. You should eat two packets of the food supplement every day, one in the mornings and one in the 
afternoon or evening. You can eat them straight from the packet and they are especially for you, and not to be 
shared with your friends or family, as they don’t have SCD. You will not know which is the normal and which is 
the super-food supplement and nor will your family, or us – until the study is finished. When you start and 
finish taking each food supplement, we will see you in a special study clinic and we will measure your height 
and weight, like we do normally. We will also take pictures of a blood vessel in your arm with a special machine 
that can “see” through your skin! This is like when a pregnant woman gets a picture of the baby in their tummy 
before the baby is born. This does not hurt at all and does not harm the baby or the mother. During the study 
you will not have to come to the normal SCD clinic as well, as we will be seeing lots of you at the special study 
clinic instead. All children taking part in this study will be visited every other week by someone from the study, 
who will deliver the food supplement and check how you are by asking your parents some questions.  
 
  
1 MIEZI MINNE 2 MIEZI MINNE 3 MIEZI MINNE 4 MIEZI MINNE 5
KIPINDI  1 BILA KITU  1 KIPINDI 2 BILA KITU 2 
VYAKULA NYONGEZA-1 VYAKULA NYONGEZA-1
AU AU
VYAKULA NYONGEZA-2 VYAKULA NYONGEZA-2
HUDHURIO LA KLINIKI
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 Musa having a picture of his blood vessel taken by Dr 
Selemani (V-FIT Dr) 
 
 
Food supplement – one dose 
 
 
Food supplement for each morning and afternoon 
of the week  
 
 
 
We think that many SCD children are experiencing more episodes of pain and illness than we know about. We 
plan to find out by visiting children and families at home once a week – and asking them! We will ask for your 
help and your families also by filling out a simple daily diary with pictures and stickers which records how you 
have felt each day. We hope this will be fun for you to do. 
 
Please feel free to take this home with you. For the study, we will ask you to sign to confirm that you 
understand and want to be in this study. You can speak to Dr J Makani: Tel: 0754 38151.
V-FIT Page 55 of 65 Version 1.1; 20th Jan2014 
MUHIMBILI UNIVERSITY OF HEALTH & ALLIED SCIENCES 
P.O Box 65001 Dar es Salaam. Tanzania 
 
INFORMED ASSENT FORM 
 
Site name Site number Serial number (site specific) Participant number 
MUHAS NA       
Vascular Function Intervention Trial (V-FIT) in Sickle cell disease 
Informed ASSENT for participating children:  
I have read or I have been read the attached information regarding the SCD study in English / Swahili (please 
circle one), a language I understand. I have also had an opportunity to ask questions and am willing to 
participate.   
 
I agree to take part in this study:  
 
Patients  
Signature or thumb print ________________________________________ Date___________________ 
 
Patients Name: ________________________________________________  Age ___________________ 
(Please print name) 
 
Parent/Caretaker 
 
I confirm that my child has had the study explained, has had the opportunity to ask questions and understands 
what will be involved for him/her and is willing to take part.  
 
 
Signature or thumbprint      _____________________________________________ Date____________ 
 
Witness’ Name: _______________________________________________________________________ 
(Please print name) 
 
I certify that the above was explained verbally to the parent/guardian, and that s/he understands the nature 
and the purpose of the study and consents to the participation in the study of the above child.  
 
I have given them the opportunity to ask questions which have been answered satisfactorily.  
 
Research Officer 
Signature _______________________________________ Date___________________ 
 
Research Officer Name: _______________________________________________ 
(Please print name) 
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CHUO KIKUU CHA TIBA NA SAYANSI MUHIMBILI 
P.0.BOX 65001, DAR-ES-SALAAM.TANZANIA 
 
FOMU YA TAARIFA 
 
      
Jina la mahali Namba ya mahali Namba ya safu(mahali halisi) Kitambulisho cha 
Utafiti 
MUHAS N/A      
 
JINA LA UTAFITI:   
Vascular Function Intervention Trial (V-FIT) in Sickle cell disease 
Majaribio Ya Muingiliano Wa Ufanyaji Kazi Wa Mishipa Ya Damu (V-FIT)  
Katika Ugonjwa  Wa Siko  Seli. 
 
WATAFITI 
Utafiti huu unaendeshwa kwa ushirikiano kati ya watafiti kutoka Uingereza na watafiti kutoka kitengo cha 
utafiti wa ugonjwa wa siko seli Muhimbili ambapo wewe ulikubali kuwa mshiriki. (Kwa maelezo ya kina 
tafadhali angalia maelezo yafuatayo hapo chini) 
 
MADHUMUNI YA UTAFITI 
Kutokana na matokeo ya utafiti tulioufanya hadi sasa tuna ushahidi wa kutosha  kushauri kwamba vyakula 
nyongeza vinaweza kuleta  manufaa katika ugonjwa wa siko seli.Tumegundua kuwa watoto wengi wenye 
ugonjwa wa siko seli wana utapia mlo na mara nyingi huwa wafupi na wembamba ukilinganisha na watoto wa 
Tanzania wenye umri kama huo wasiokuwa  na ugonjwa wa siko seli.Ukuaji duni unaambatana na matokeo 
mabaya ya afya  katika magonjwa mengi yakiwemo na magonjwa ya siko seli.Tumeona pia kuwa wingiwa 
virutubisho lishe katika damu ni pungufu sana kwa watu wenye ugonjwa wa siko seli ambao huumwa sana au 
mara kwa mara   ukilinganisha na wale wenye kuumwa kidogo au mara chache u. Wingi wa virutubisho lishe  
unadhaniwa kuwa muhimu katika kuwezesha mishipa ya damu kumudu vyema kazi ya kusafirisha 
damu.Tunafahamu kuwa iwapo mishipa hiyo haitafanya kazi ipasavyo,inaweza kuchangia kwa baadhi ya dalili 
na matokeo ya muda mrefu  ya ugonjwa wa siko seli.Pia tunadhani kuwa dawa ya klorokwini tuliyokuwa 
tukiwapa wagonjwa kama tiba ya malaria inaweza kuwa na matokeo ya kufaa katika ufanyaji kazi wa mishipa ya 
damu,Lakini hatuna hakika kiasi gani kinahitajika kwa ili kupata matokeo hayo. 
 
Virutubisho lishe hutumika nchini Tanzania kutibu na kuzuia utapiamlo.Hatuna hakika kama Virutubisho 
lishekama hivi vyenye vitamin na madini vitasaidia kuongeza ukuaji na matokeo mengine kwa watoto wenye 
siko seli,kama vile  kupunguza tatizo la upungufu mkubwa wa damuTunapenda pia kufahamu ikiwa kuongeza  
zaidi aina fulani kwenye hivi hivi virutubisho lishe na kutoa kidogo  lakini mara nyingi kwa siku  dawa ya  
klorokwini kinaweza kuboresha ufanyaji kazi wa mishipa ya damu  kwa wagonjwa wa siko seli.Ili 
kufahamu,inabidi kulinganisha  ukuaji na ufanyaji kazi wa mishipa ya damu kwa watoto baada ya muda wa 
kutowapa Virutubisho lishena vile vya  kawaida ukilinganisha na wakati wanapotumia Virutubisho lishecha 
kawaida na wakati wa kutumia Virutubisho lisheviivyoongezewaa virutubisho na   dozi tofauti ya klorokwini 
kutoka ile ya kawaida. 
 
Tunadhani kuwa watoto wengi wenye ugonjwa wa siko seli  wanapatwa na  na maumivu makali pamoja na 
kuumwa  mara nyingi zaidi kulinganisha na taarifa ambazo huwa  tunakusanya   wanapolazwa  katika Hospitali 
ya Taifa ya Muhimbili.Pia tunadhani kuwa Virutubisho lishe vinaweza  kuwa na uhusiano na  maumivu makali 
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yanayowapata watoto wenye ugonjwa wa siko seli. Kudhihirisha  hayo inabidi tuweze kupima  kiusahihi.Hivyo 
basi tunataka kukusanya taarifa sahihi juu ya idadi ya matukio ya maumivu  na homa, kwa kuomba familia zao 
zitusaidie kurekodi matukio haya pindi yatokeapo kwa mtoto pamoja na kukubali kupigiwa simu, na  
kuwatembelea watoto na familia zao majumbani. 
 
NANI ATAHUSIKA KATIKA UTAFITI  
Tunawakaribisha watoto wenye umri kati ya miaka 8 hadi 11 ambao tayari wanashiriki katika utafiti wa siko seli 
Muhimbili na wawe ni wakazi wa kudumu wa vitongoji vya Dar-es-salaam kushiriki katika utafiti huu.Watoto 
watakaoonekana wana utapiamlo mkali hawatashirikishwa kwenye utafiti ila watapewa rufaa kwenda katika 
kitengo kinachojihusisha na kutibu utapimlo katika Hospitali ya Taifa Muhimbili kwa matibabu.Watoto wenye 
matatizo mengine ya kiafya kama vile kifafa , kifua kikuu nakadhalika au wale ambao wanatumia  aina fulani ya 
dawa hawatashirikishwa  katika utafiti huu. 
 
NINI KITAHUSIKA KATIKA USHIRIKI   
 
Kujibu maswali yote haya, watoto watapewa moja kati ya aina mbili ya vyakula nyongeza mwanzo wa utafiti 
kwa kipindi cha miezi 4, ikifuatiwa na kipindi cha miezi 4 ambacho hawatapewa vyakula nyongeza. Halafu 
itafuatiwa na kipindi kingine cha miezi 4 ambapo watapewa aina tofauti ya vyakula nyongeza na mwisho kipindi 
kingine cha miezi 4 bila kupewa vyakula nyongeza, kwahiyo zoezi zima la utafiti litachukua kipindi cha miezi 
miezi 16.Si mchunguzi, au wewe na mtoto wako watakaojua ni aina hipi ya chakula nyongeza mtoto anapewa 
baada ya kumalizika kwa utafiti. Watoto wote watakaoshiriki kwenye utafiti huu watatembelewa majumbani 
na mfanyakazi wa utafiti mara moja kila baada ya  wiki 2 kwa kipindi chote cha utafiti. Ambaye atawapatia 
vyakula nyongeza na dawa ya maji ya klorokwini, katika wiki ya kati mfanyakazi wa utafiti atawapigia simu. 
 
 
 
Ikiwa utakubali kushiriki katika utafiti huu mtoto atapangwa katika moja ya makundi mawili kwa njia ya bahati 
nasibu itakayofanyika kwa kutumia bahasha zilizofungwa kabisa, , kisha kila kundi litapewa ama  vyakula 
nyongeza maalumu au vyakula nyongeza vya mwanzo. 
• Katika kipindi cha utafiti, watoto hawataruhusiwa kutumia vitamin wala madini ya nyongeza ila tu kwa 
kuidhinishwa na daktari, ambaye atakuwa na taarifa kuwa mtoto wako anatumia vyakula nyongeza 
vinavyotolewa katika utafiti huu.. 
• Kwa wakati ule ambao watoto watakuwa hawapewi vyakula nyongeza vya utafiti watoto 
wataruhusiwa kuendelea kutumia dawa yao ya Folic Acid kama kawaida. , Lakini kwa kile kipindi 
watakachokuwa wanapewa vyakula nyongeza hawatahitajika kutumia dawa zao za Folic acid  kwani  
tayari vyakula nyongeza watavyokuwa wanapewa vinayo folic acid. 
 
1 MIEZI MINNE 2 MIEZI MINNE 3 MIEZI MINNE 4 MIEZI MINNE 5
KIPINDI  1 BILA KITU  1 KIPINDI 2 BILA KITU 2 
VIRUTUBISHO LISHE-1 VIRUTUBISHO LISHE-1
AU AU
VIRUTUBISHO LISHE-2 VIRUTUBISHO LISHE-2
MIEZI KUMI NA SITA
HUDHURIO LA KLINIKI
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 (mchoro wa kungara utatumika katika maelezo) 
 
Taratibu za kuhudhuria kliniki  
Watoto watakaoshiriki katika  utafiti huu watatkiwa kuhudhuria kliniki maalum 5 za utafiti kama ifuatavyo; 
yakwanza wakati wa kuanza halafu  baada ya miezi 4, 8, 12 & 16..Hizi zitakuwa badala ya kliniki zako za siko seli 
za kawaida,kwa hiyo mtoto hatahitaji tena  ya ziada .Kila unapohudhuria kliniki hizi maalum   kwa ajili ya utafiti 
huu,vipimo vifuatavyo vitachukuliwa. 
• Kipimo cha damu. Mtoto atachukuliwa kiasi kidogo cha damu mls 5 au ujazo wa kijiko cha chai kama 
ambavyo huchukuliwa ahudhuriapo kliniki yake ya kawaida.. 
• Urefu na uzito wa watoto vitapimwa, halafu pia watapimwawingi wa mafuta na misuli kwa kutumia 
mashine maalum ambapo mwanao atasimama kwenye mashine hiyo na kushika mikono yake kwenye 
mikono ya mashine kwa dakika moja. 
• Ufanyaji kazi wa mishipa ya damu utapimwa katika mahudhurio manne ya kwanza kwa kutumia mashine 
maalum ambayo inatumia sauti kwa kupiga picha za ndani ya miili yetu-sawa na na mashine tunazotumia 
tunavyomchunguza mtoto ndani ya matumbo ya mama waja wazito (ultra sound)  au sawasawa na 
mashine tunayotumia wakati tunavyopima spidi ya damu inavyosafiri ndani ya mishipa ya damu katika 
kichwa ambayo tunaita “TCD”Mtoto wako pengine atakuwa ameshafanyiwa kipimo cha TCD kama 
sehemu ya utafiti wa ugonjwa wa siko seli,kipimo hiki huwa kinafanywa mara kwa mara katika sehemu 
zingine duniani zinazojihusisha na matibabu ya ugonjwa wa siko seli. Tutapima ufanyaji kazi wa mshipa 
mkubwa wa damu katika mkono kwa kupiga picha wakati mshipa umekazwa na wakiti umelegezwa kama 
tufanyavyo wakati wa kupima shinikizo la damu (BP) kila uhudhuriapoe kliniki ya siko seli.Tofauti iliyopo 
ni kipimo hiki kitachukua muda kidogo zaidi kulinganishwa na wakati wa kupima shinikizo la damu lakini 
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hautazidi dakika 5.Mwisho tutachukua picha za mishipa ya damu kabla na baada ya dakika 5 baada ya 
kupewa dozi kidogo ya dawa iitwayo glyceryl-trinitrate ambayo mtoto atawekewa chini ya ulimi. Dawa 
hiyo ni salama kabisa na hutumika kwa kiasi kikubwa kuimarisha utendaji kazi wa mishipa ya damu na 
mapigo ya moyo kwa wagonjwa wenye matatizo ya moyo na mishipa ya damu. 
 
  
(michoro ya kungara na picha za chumba na watoto wanaofanyiwa zoezi hilo) 
 
 
Kutembelea majumbani na ushiriki wa wazazi katika kukusanya takwimu. 
• Familia zitaombwa kujaza   kumbukumbu za matukio ya maumivu katika kitabu maalum ambacho 
kitakuwa na michoro ili kurahisha ujazaji.Katika kitabu hiki watajaza pia kiasi cha maumivu au ukali 
pamaja na matibabu yeyote ikiwa alitibiwa. 
 
Kama utapata tatizo, ugumu au wasiwasi wowote kutokana na kushiriki katika utafiti huu, utamjulisha mtafiti 
atakayekuwa anakutembelea nyumbani.Tutajitahidi kuhakikisha kuwa unatembelewa na mtafiti huyohuyo kila  
wiki. 
  
Matembezi ya nyumbani ya kila wiki ni sehemu muhimu katika utafiti hu na ushiriki wako ni wa 
maana.Tunadhani tunaweza kujifunza mengi kuhusu siko seli kwa kupata uzoefu wako kama mzazi,nje ya 
mazingira ya  kawaida ya hospitali. 
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Je sampuli za damu zilizochukuliwa kutoka kliniki za utafiti zitatumikaje? 
Tutachukua  sampuli moja tu ya damu kutoka kwenye kliniki za utafiti.Vipimo vya kawaida ambavyo huwa 
vinavyofanyika kwenye kliniki za siko seli vitafanyika kama vilefull blood picture na vipimo vya malaria kama 
vitahitajika.Sampuli itakayobaki itatumika kupima viashiria maalum vinavyohusiana na utendaji kazi wa   
mishipa ya damu. Baadhi ya vipimo vitafanyika kwenye maabara ya siko seli,hapa Muhimbili na vingine 
vitatakiwa kufanyika katika maabara za uingereza.Sampuli zozote zitakazobakia zitahifadhiwa kwa muda mrefu 
kwa ajili ya tafiti zingine za baadae zinazosabiana na ongezeko la uelewa wa ugonjwa wa siko seli.Hii ni sawa na 
inavyotokea kwa sampuli zinazokusanywa katika kliniki za kawaida za siko seli. 
 
 
FAIDA YA UTAFITI 
Hakutakuwa na faida ya moja kwa moja au ya kifedha kwa washiriki wa utafiti huu.Ushiriki wako utatusaidia 
kujua iwapo vyakula nyongeza pamoja na utoaji wa kila siku wa dawa klorokwini kulinnganishwa na utoaji wa 
klorokwini kwa wiki una faida pekee kwa wagonjwa wa siko seli.Ingawa tunatumia  vyakula nyongeza na 
klorokwini ambayo tayari ilishatumika kwa wagonjwa wa siko seli,bado ni muhimu sana tuwe ushahidi na 
uhakika kwamba matumizi haya ni yenye manufaa, salama na yanakubalika na  familia. 
 
ATHARI MUHIMU ZA UTAFITI 
• Utafiti huu unaweza kuwa na athari i ndogo sana kwa watoto kama vile kupata  aleji itokanayo na 
vyakula nyongeza.Tutajitahidi kupunguza  athari hiyo kwa kuwapatia kwanza kiasi kidogo cha vyakula 
nyongeza kama majaribia hapa kwenye kliniki 
• Kiasi cha  damu itakayochukuliwa ni ndogo na haiwezi kuleta athari zozote kwa mtoto kwani ni kiasi 
kidogo zaidi ya damu itolewayokwenye kliniki za siko Watoto wengine wanaweza kijisikia vibaya 
kutokanwa na kukazwa mkono wakati wa kufanya kipimo maalum cha kuangalia utendaji kazi wa mishipa 
ya damu hali hii pia inaweza kutokea baada kipimo ya kulegezwa ingawa hatujawahi kushuduia hili 
likitokea. .Ili kupunguza athari hii  tutahakikisha  mtoto wako anakuwa mtulivu wakati wa kipimo na 
baada ya kipimo  tutakuomba wewe na mtoto wako kupumzika  sehemu salama tutakayoiandaa  kwa saa 
moja baada ya kumaliza  kufanyiwa kipimo cha kuangalia  ufanyaji kazi wa mshipa wa damu ili 
kuhakikisha kuwa  hakuna madhara yaliyotokea au kama kuna madhara yametokea basi tuweze 
kuyatibia. 
• Kama kawaida ya dawa yeyote ile  huwa na athari ndogo  hivyo basi  mtoto wako anaweza akapata athari 
hizo kutokana na  matumizi ya klorokwini kila siku au kila wiki.Hata hivyo nyingi ya athari hizo ni za muda 
mfupi na hazina madhara, lakini tutafuatilia matukio yote hayo kwa ukaribu na pia tunakuomba utupe 
taarifa ya tatizo lolote litakalotokea kwa mtoto wako au kama kuna jambo lolote unalohitaji ufafanuzi 
wakati wa kuhudhuria kliniki za kila wiki au piga simu kwenye namba za simu za wagonjwa wa siko seli. 
 
UHURU WA KUSHIRIKI KATIKA UTAFITI 
Tungependa kusisitiza kuwa ushiriki wako katika utafiti huu ni wa hiari kabisa. Ni uamuzi wako.Ukiamua 
kutokushiriki; kamwe haitaathiri matibabu au uangalizi utakaoupata kutoka hapa hospitali au ushiriki wako 
katika utafiti unaoendelea, kwa kuongezea uko huru kujitoa kwenye 
 ushiriki katika utafiti huu(na pia ukipenda hata katika utafiti unaoendelea) wakati wowote ule utakapojisikia 
kufanya hivyo na sisi tutakuondoa kwenye utafiti mara moja.Ikiwa pia utapendelea tuharibu  sampuli yeyote 
iliyohifadhiwa tuliyo nayo tutafanya hivyo.Maamuzi yeyote ya namna hiyo yataheshimika na hayataathiri  
ubora wa huduma za  afya tutakazokupa wewe na mtoto wako. 
 
 
V-FIT Page 61 of 65 Version 1.1; 20th Jan2014 
USIRI 
Taarifa zote zilizopatikana kutoka kwa mtoto wako na familia yako zitakuwa za siri na kwa kuongezea pamoja  
kutumia namba yako ya sasa ya siko seli, tutakupatia pia namba nyingine mpya kwa ajili ya utafiti huu..Ni 
Mtafiti Mkuu tu au mtu atakayeidhinishwa na yeye ndiye ataweza kuunganisha taarifa binafsi kwenda kwa 
washiriki wa utafiti. 
 
WATAFITI   
Dr. Sharon Cox (London School of Hygiene &Tropical Medicine, UK) 
Dr. Julie Makani (Muhimbili University of Health &Allied Scieences.Tanzania) 
Professor Charles Newton (UCL-Institute of Child Health, UK&KEMRI-Kilifi, Kenya) 
Professor Fenella Kirkham (UCL-Institute of Child Health,UK) 
Professor Andrew Prentice (London School of Hygiene &Tropical Medicine, UK) 
Professor Julian Halcox (University of Cardiff, UK) 
 
Tafadhali jisikie huru kuuliza maswali yeyote kuhusu taarifa ambazo tumekupatia hivi au jambo lolote 
linalohusiana na ugonjwa wa Siko Seli na matunzo/huduma ya mtoto wako.  tutafurahi ya kukupatia taarifa 
zaidi iliyoandikwa, kuhusiana na  aina tofauti za virutubisho vilivyopo kwenye  vyakula nyongeza pamoja na 
dawa  ya klorokwini kama utahitaji (inapatikana kwa kiingereza) 
 
Kuna taarifa zaidi katika mfumo wa majarida, vipeperushi na machapisho ambazo zipo  kwa ajili yako ili usome 
zaidi kuhusu ugonjwa wa siko seli. Taasisi ya THE SICKLE CELL FOUNDATION IN TANZANIA pia inazo taarifa  
kuhusiana na  ugonjwa wa siko seli na wangefurahi  kusikia kutoka kwako juu ya wasiwasi wowote au maswali 
ambayo unayo(tafadhali ulizia namna ya kuwasiliana) 
 
Tafadhali jisikie huru kuchukua taarifa hizi kwenda nazo nyumbani na unaweza kuwasiliana nasi au kutuliza 
maswali zaidi wakati utakapokuja tena kliniki.. 
 
Kwa ajili ya utafiti tutakuomba uweke saini yako katika karatasi hii ili kuhakikisha kuwa umepokea taarifa hizi na 
kwamba umekubali kwa hiari kushiriki katika utafiti huu. 
 
Kama kuna taarifa yeyote ambayo utahitaji kuhusu taratibu ya utafiti tafadhali omba ili uonane na Dr.J Makani, 
Idara ya Magonjwa ya damu katika Chuo Kikuu Kishiriki cha Sayansi na Tiba Muhimbili (MUHAS).Simu +255 
0754 381551 au watafiti wengine.Iwapo una maswali juu ya haki yako kama mshiriki, unaweza kuwasiliana na 
Mwenyekiti wa  Kamati ya Utafiti na Mawasiliano ya Chuo kikuu cha muhimbili (MUHAS)  P.O.BOX 65001 Simu 
2150302 Dar-es-salaam 
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CHUO KIKUU CHA TIBA NA SAYANSI MUHIMBILI 
P.0.BOX 65001, DAR-ES-SALAAM.TANZANIA 
 
FOMU YA TAARIFA 
 
      
Jina la mahali Namba ya mahali Namba ya safu(mahali halisi) Kitambulisho cha 
Utafiti 
MUHAS N/A      
Majaribio Ya Muingiliano Wa Ufanyaji Kazi Wa Mishipa Ya Damu (V-FIT)  
Katika Ugonjwa Wa Siko  Seli. 
 
Taarifa ya idhini kwa washiriki: 
Nimesoma/nimesomewa taarifa iliyoambatanishwa kuhusu utafiti wa ugonjwa wa siko seli kwa lugha ya 
Kiswahili, lugha ninayoizungumza kiufasaha.pia nimepata nafasi ya kujadili na kuuliza maswali kwa wachunguzi 
na nimeridhika kwamba nimeelewa utafiti huu unahusu nini na kujibiwa maswali yangu 
 
Nimekubali/kumruhusu mtoto wangu (aliyetajwa hapo chini) kushiriki katika utafiti huu 
 
(1)……………………………………………………….. 
 
Mgonjwa/Mzazi/Mlezi 
Sahihi au dole gumba………………………..Tarehe…………………. 
 
Jina la Mzazi/Mlezi…………………………………………… 
                                        (herufi kubwa tafadhali) 
 
Shahidi 
Sahihi (kama mdhaminiwa hajui kusoma)……………………Tarehe……………. 
 
Jina la shahidi………………………………………………. 
                                           (herufi kubwa tafadhali) 
 
Ninathibitisha kwamba yaliyoandikwa hapo juu yameelezwa kwa mdomo kwa mzazi/mlezi na kwamba 
ameelewa nia na madhumuni ya utafiti na kutoa idhini kwa washiriki katika utafiti kwa wagonjwa waliotajwa 
hapo juu. 
 
Nimewapa nafasi ya kuuliza maswali ambayo yamejibiwa kwa kuridhisha. 
 
Afisa wa Utafiti 
Sahihi……………………………………Tarehe………………………… 
 
Jina la Afisa wa Utafiti……………………………………………… 
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CHUO KIKUU CHA TIBA NA SAYANSI MUHIMBILI 
P.0.BOX 65001, DAR-ES-SALAAM.TANZANIA 
 
FOMU YA TAARIFA (ASSENT) 
 
      
Jina la mahali Namba ya mahali Namba ya safu(mahali halisi) Kitambulisho cha 
Utafiti 
MUHAS N/A      
 
JINA LA UTAFITI:   
Vascular Function Intervention Trial (V-FIT) in Sickle cell disease 
Majaribio Ya Muingiliano Wa Ufanyaji Kazi Wa Mishipa Ya Damu (V-FIT)  
Katika Ugonjwa  Wa Siko  Seli. 
 
UTAFITI 
Hatujui kuwa Vyakula nyongeza au “ vyakula nyongeza bora”  ambavyo vina  virutubisho lishe  zaidi vinaweza 
kuboresha ukuaji na kupunguza matokeo ya ugonjwa wa siko seli kwa watoto kama wewe mwenye ugonjwa wa 
siko seli.Watoto wenye siko seli Tanzania wanashauriwa kutumia kidonge cha klorokwini au klorokwini ya maji 
mara moja kwa wiki ili kuwazuia wasipate malaria. Hatujui kama iwapo watatumia  kiasi kidogo cha  cha 
klorokwini kila siku badala ya wiki moja inaweza ikaleta matokeo mazuri katika ugonjwa wa siko seli zaidi  ya 
kukuzuia kupata malaria. Kupata majibu kutoka maswali hayo, inatubidi kulinganisha ni haraka namna gani 
watoto wanavyokua (mabadiliko ya urefu, uzito kupita mda)na kupiga picha ya mishipa ya damu wakati watoto 
hawatumii vyakula nyongeza na wakati watoto wanatumia vyakula nyongeza bora au vya kawaida. 
 
Kama utashiriki katika utafiti huu, utapewa mojawapo ya vyakula nyongeza pamoja na dawa ya maji ya 
klorokwini. Utakapomaliza kutumia vyakula nyongeza hivi utakuwa na kipindi kingine fulani ambacho utakaa 
bila kupewa vyakula nyongeza. Kisha utapewa aina nyingine tofauti ya vyakula nyongeza. Itabidi ule pakiti mbili 
za vyakula nyongeza kila siku, moja asubuhi na moja mchana au jioni.Unaweza kula moja kwa moja kutoka 
kwenye paketi na vyakula hivi viko maalumu kwa ajili yako, na siyo kwa kuwapa rafiki zako au mwanafamilia, 
kwani wao hawana siko seli. Wewe sisi au mzazi wako tatuwezi kujua ni aina ipi ya vyakula nyongeza (kati ya ile 
ya kawaida au vyakula vyongeza bora) utakayokuwa unatumia mpaka mwisho wa utafiti. Utakapoanza na 
kumaliza kutumia kila vyakula nyongeza tutakuona katika cliniki maalumu ya utafiti na tutakupima urefu na 
uzito kama kawaida tunavyofanya.Pia tutapiga picha za mishipa ya damu kwenye mkono wako kwa kutumia 
mashine maalumu ambayo inaweza kuona ndani ya ngozi yako. Mashine hii ni sawa na ile ambayo hutumika 
mama mja mzito anapopigwa picha ya mtoto wake ndani ya tumbo kabla mtoto wake hajazaliwa. Kipimo hiki 
hakiumizi kabisa wala hakiwezi kumdhuru mtoto au mama.Wakati wa utafiti huu hutahitajika kuhudhuria kliniki 
yako ya kawaida ya siko seli, kwani badala yake tutakuwa tunawaona wengi wenu katika kliniki maalumu ya 
utafiti. Watoto wote wanaoshiriki katika utafiti huu watatembelewa kila baada ya wiki moja kupita na 
mfanyakazi kutoka katika utafiti, ambaye atatoa vyakula nyongeza na kuchunguza jinsi afya yako ilivyo na 
kukuuliza maswali kadhaa. 
 
 
  
1 MIEZI MINNE 2 MIEZI MINNE 3 MIEZI MINNE 4 MIEZI MINNE 5
KIPINDI  1 BILA KITU  1 KIPINDI 2 BILA KITU 2 
VYAKULA NYONGEZA-1 VYAKULA NYONGEZA-1
AU AU
VYAKULA NYONGEZA-2 VYAKULA NYONGEZA-2
HUDHURIO LA KLINIKI
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 Musa having a picture of his blood vessel taken by Dr 
Selemani (V-FIT Dr) 
 
 
Food supplement – one dose 
 
 
Food supplement for each morning and 
afternoon of the week  
 
 
 
Tunadhani kuwa watoto wengi wenye ugonjwa wa siko seli wanapata taabu sana ya maumivu ya mara kwa 
mara kuliko tunavyojua. Tuna mpango wa kulichunguza jambo hili kwa  njia ya kuwatembelea watoto na familia 
zao majumbani mara moja kwa wiki-na kuwahoji.Tutaomba msaada wako na wa familia yako pia kwa kujaza 
kitabu maalum ambacho ni  rahisi kwani kina maelekezo ya picha vibandiko ambamo utawekarekodi za 
maendeleo yako ya namna unavyojisikia  kila siku.Tuna imani utafurahia kujaza kitabu hiki. 
 
Tafadhali jisikie huru na chukua hii nyumbani. Kwa ajili ya utafiti tutakuomba utie saini kutuhakikishia kuwa 
umeelewa na ungependa kushiriki kwenye utafiti. Unaweza kuongea na Dr Makani: Tel: 0754 381551. 
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CHUO KIKUU CHA TIBA NA SAYANSI MUHIMBILI 
P.0.BOX 65001, DAR-ES-SALAAM.TANZANIA 
 
FOMU YA TAARIFA (ASSENT) 
 
      
Jina la mahali Namba ya mahali Namba ya safu(mahali halisi) Kitambulisho cha 
Utafiti 
MUHAS N/A      
Majaribio Ya Muingiliano Wa Ufanyaji Kazi Wa Mishipa Ya Damu (V-FIT)  
Katika Ugonjwa  Wa Siko  Seli. 
 
Taarifa ya idhini kwa washiriki: 
Nimesoma/nimesomewa taarifa iliyoambatanishwa kuhusu utafiti wa ugonjwa wa siko seli kwa lugha ya 
Kiswahili, lugha ninayoizungumza kiufasaha.pia nimepata nafasi ya kujadili na kuuliza maswali kwa wachunguzi 
na nimeridhika kwamba nimeelewa utafiti huu unahusu nini na kujibiwa maswali yangu 
 
Nimekubali/kumruhusu mtoto wangu (aliyetajwa hapo chini) kushiriki katika utafiti huu 
 
(1)……………………………………………………….. 
 
Mgonjwa/Mzazi/Mlezi 
Sahihi au dole gumba………………………..Tarehe…………………. 
 
Jina la Mzazi/Mlezi…………………………………………… 
                                        (herufi kubwa tafadhali) 
 
Shahidi 
Sahihi (kama mdhaminiwa hajui kusoma)……………………Tarehe……………. 
 
Jina la shahidi………………………………………………. 
                                           (herufi kubwa tafadhali) 
 
Ninathibitisha kwamba yaliyoandikwa hapo juu yameelezwa kwa mdomo kwa mzazi/mlezi na kwamba 
ameelewa nia na madhumuni ya utafiti na kutoa idhini kwa washiriki katika utafiti kwa wagonjwa waliotajwa 
hapo juu. 
 
Nimewapa nafasi ya kuuliza maswali ambayo yamejibiwa kwa kuridhisha. 
 
Afisa wa Utafiti 
Sahihi……………………………………Tarehe………………………… 
 
Jina la Afisa wa Utafiti……………………………………………… 
 
 
 
 
 
 
